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ABSTRACT
The transcription factor NF-κB plays a central role in many aspects of biological
processes and diseases, such as inflammation and cancer. Although it has been suggested that
NF-κB is critical in tumorigenesis and tumor progression, the molecular mechanism by
which NF-κB is activated in solid tumor remains largely unknown. In the current work, we
focus on growth factor receptor-induced NF-κB activation and tumor progression, including
epidermal growth factor receptor (EGFR)-induced NF-κB in lung cancer and heregulin
receptor (HER2)-induced NF-κB in breast cancer. We found that Mucosa-associated
lymphoma translocation protein 1 (MALT1), also known as paracaspase, is required for
EGFR-induced NF-κB activation by recruiting E3 ligase TRAF6 to the IKK complex. In
addition, MALT1 also contributes to many malignant phenotypes, including tumor cell
proliferation, survival, migration and metastasis. Furthermore, by generating transgenic mice
in which EGFR-associated lung adenocarcinoma will be developed in the absence of
MATL1, we found that MALT1 specifically contributes to the EGFR- but not K-ras-induced
lung adenocarcinoma by activating both NF-κB and STAT3 pathway, suggesting a crucial
role of MALT1 in EGFR-associated lung cancer progression. In a separate study, we found
that MALT1, together with its interaction partners CARMA3 and BCL10 (also known as the
CBM complex), is required for HER2-induced NF-κB activation. Consistently, the CBM
complex contributes to malignant phenotypes in breast cancer cells, including proliferation,

vii

survival, migration, invasion and metastasis. Furthermore, we showed that the development
of mammary tumor was delayed in MALT1-deficient mice (MMTV-Neu; Malt1-/-), indicating
that MALT1 contributes to the onset and progression of breast cancer in vivo. To further
explore the role of MALT1 in cancer therapy, we found that MALT1 and the CBM complex
are involved in resistance of chemotherapy induced apoptosis. MALT1 deficiency promotes
doxorubicin-induced apoptosis. Mechanistically, the CBM complex is required for DNA
damage-induced NF-κB activation, which antagonizes doxorubicin-induced apoptosis. In
summary, our studies have revealed the multi-functional roles of MALT1 and the CBM
complex in growth factor-associated solid tumors and cancer therapy.
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CHAPTER 1: INTRODUCTION
1.1 General overview of lung cancer and breast cancer
1.1.1.1 Overview of lung cancer
According to the cancer statistics reported in 2008, lung cancer is the leading cause of
cancer death in the United States and worldwide (Jemal et al. 2008). About 85% of lung
cancers are non-small cell lung cancer (NSCLC), while 15% of lung cancers are small-cell
lung cancers. As most NSCLC are diagnosed at the advanced stage, it is associated with a
poor prognosis with a 5-year survival rate at 15.9% (Ettinger et al. 2013). The NSCLC can be
further divided into three subtypes according to the pathological findings, adenocarcinoma
(ADC, around 50%) , squamose-cell carcinoma (SCC, around 40%), and large-cell lung
cancer. ADC generally occurs in more distal airways and is the associated with never
smokers, while SCC generally occurs in more proximal airways and is closely associated
with smoking. Recent studies suggest that the susceptibility and risk of lung cancer could be
increased in patients with inherited genetic alternations, including rare mutations in tumor
suppression genes such as p53, retinoblastoma (Rb), and oncogenes such as EGFR
(epidermal growth factor receptor) gene (Sanders et al. 1989, Hwang et al. 2003, Bell et al.
2005). Genome wide association study (GWAS) also indicates an association between lung
cancer susceptibility and single nucleotide polymorphisms (SNPs) at 15q24-15q25.1 (Amos
et al. 2008, Hung et al. 2008, Thorgeirsson et al. 2008). Lung cancers at the early stage are
often asymptomatic. Therefore, early diagnosis of lung cancer is extremely important. The
diagnosis of lung cancer includes imaging tests (X-ray, CT scan and positron emission
tomographyscan), biopsy and sputum cytology. In term of lung cancer treatment, surgery is
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a preferred treatment for patients with early stage of lung cancer. However, most patients
with advanced or metastatic lung cancer are not suitable for surgery treatment. In addition to
surgery, other treatment options includes chemotherapy, radiation therapy, targeted therapy
and immunotherapy. For example, lung cancers with activating EGFR mutations can be
treated with targeted therapy by using EGFR tyrosine kinase inhibitors (EGFR-TKIs), such
as erlotinib and gefitinib (Gazdar 2009). Noticeably, immunotherapy recently becomes an
emerging and promising way to treat lung cancer (Massarelli et al. 2014). In March 2015, the
FDA approved the PD-1 checkpoint inhibitor nivolumab for treatment of advanced squamous
NSCLC that has stopped responding to chemotherapy reagent . This approval is based on the
data of a phase III clinical trail showing that patients receiving nivolumab lived an average
3.2 months longer than patients who receiving standard chemotherapy (Brahmer et al. 2015).

1.1.1.2 Molecular origins of lung cancer
Activating K-ras mutation is responsible for about 15%-25% of NSCLC. An amino
acid changing mutation at the position 12, 13 or 61 will generate the constitutive activating
form of K-ras, which has a strong transformation potential (Bos 1989). The activating K-ras
will constantly activates MEK-ERK pathway to send a constitutive proliferation signal to the
cell (McCormick 2015). Despite tremendous efforts spent on identifying drugs that
specifically inactivate mutant K-ras, targeting K-ras associated tumors is still difficult
(McCormick 2015). Given the structural similar of four Ras isoforms-H-Ras, N-Ras, KRas4a, and K-Ras4B, it is difficult to achieve high specificity of mutant K-ras alone.
However, a recent study reported the development of small molecules irreversibly bind to
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oncogenic K-Ras (G12C) and induce apoptosis in K-ras (G12C)-associated lung cancer cells
(Ostrem et al. 2013). Therefore, development small molecules that specifically target
oncogenic K-ras is still under insensitive investigation.
In comparison, EGFR mutation accounts for nearly 10% of NSCLC in the United
States and 35% of NSCLC in Asia (Herbst et al. 2008). Two most frequent (more than 80%
in total) mutations of EGFR involve in-frame deletion of exon 19 and L858R mutation in the
exon 21. Both EGFR mutants become constitutively active and activates a number of
downstream pathways, including PI3K-AKT, RAS-MAPK and NF-κB pathways (Sharma et
al. 2007). Therefore, oncogenic EGFR signaling promotes cell proliferation, survival and
metastasis (Sharma et al. 2007). Fortunately, lung cancer with EGFR mutations can be
treated by target therapy using EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib and
gefitinib (Gazdar 2009). Although lung cancers with EGFR mutations usually have an initial
response to EGFR TKIs, they quickly develop drug resistance to EGFR TKIs by generating
new mutations. For example, NSCLCs with EGFR T790M mutations are not responsive to
EGFR TKIs (Kobayashi et al. 2005, Kosaka et al. 2006). Amplification of porto-oncogene
MET is another mechanism in which EGFR mutant NSCLCs become resistance to EGFR
TKI treatment (Bean et al. 2007, Engelman et al. 2007). While K-ras and EGFR mutations
are two major mutations in NSCLC, other mutations also contributes to the tumorigenesis of
NSCLC, such as ALK (anaplastic lymphoma kinase) rearrangement (Solomon et al. 2009),
BRAF mutations (Davies et al. 2002), and PTEN (Phosphatase and Tensin homolog)
downregulation (Soria et al. 2002).
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1.1.1.3 Mouse models in lung cancer
Mouse models are extremely powerful preclinical models to investigate the
mechanisms by which human cancers develop in vivo. Based on the genetical alternations in
human NSCLC, genetically engineered mouse (GEM) models for lung cancers have been
generated by introducing mutations in human NSCLC. For example, using the Cre-Lox based
expression system (Sauer 1987, Sauer and Henderson 1988), Jackson et al. generated a
mouse model in which murine lung adenocarcinoma can be developed in vivo by conditional
expression of oncogenic K-ras induced by adenoviral Cre recombinase (Jackson et al. 2001).
The histology of K-ras-induced murine carcinoma closely resembles that in human NSCLC
(Jackson et al. 2001), suggesting that murine models of lung cancers are biologically related
to human lung cancer. In order to specifically achieve inducible expression of mutant K-ras
in type II alveolar epithelial cells in mice, Fisher et al. generated a conditional expression of
activating mutant K-ras-induced lung cancer model by crossing a tetracycline operatorregulated oncogenic K-ras with the clara cell secretory protein-reverse tetracycline activator
(CCSP-rtTA) mice (Fisher et al. 2001). In this mouse model, lung adenocarcinoma can be
induced by feeding mice with doxycycline (Fisher et al. 2001). Subsequently, through a
similar approach, Politi et al. generated a mouse model in which EGFR-mediated lung
adenocarcinoma (EGFRL858R;CCSP-rtTA and EGFRΔL747–S752;CCSP-rtTA) can be induced by
feeding mice with doxycycline (Politi et al. 2006). In addition to EGFR and K-ras, other
genetic mutations/amplification/deletion based murine lung cancer models are also available
(Tichelaar et al. 2000, Zhao et al. 2001, Meuwissen et al. 2003). These murine models
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provided excellent tools to study the development of human lung cancer in the context of
complicate genetic settings.

1.1.2.1 Overview of breast cancer
Breast cancer is the leading cause of cancer death in women, and is the second most
common type of cancer worldwide (Warrier et al. 2015). Breast cancer can be categorized
into two major categories: noninvasive breast cancer, also known as in situ breast cancer, in
which tumor cells remains in particular location in the breast and do not spread across
surrounding tissues (Webb and Koch 1997); invasive breast cancer, which is also known as
infiltrating breast cancer, in which tumor cells great normal tissue and spread across other
parts of tissues and distant organs in the body (Weigelt et al. 2005). The invasive breast
cancer can be further divided into two types: invasive ductal carcinoma (IDC), in which
cancer originates from the mild ducts; invasive lobular carcinoma (ILC), in which cancer
originates from lobules. According to the molecular characteristics and pathology of
invasive breast cancer, it can be also decided in to several subgroups, including endocrinesensitive breast cancer, HER-2 positive breast cancer, triple-negative breast cancer,
inflammatory breast cancer, medullary carcinoma, metaplastic carcinoma, mutinous
carcinoma, papillary carcinoma, tubular carcinoma, Paget’s disease and male breast breast
cancer. Breast cancer can show no symptom at the early stage and shows symptoms at the
late stages, including skin changes, pain, irritation and symptoms of local inflammation. Due
to the asymptomatic feature of breast cancer, early diagnosis and prevention screening is
critical. According to the american cancer society beast cancer screening guideline, it is
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suggested that women with average risk of breast cancer should take annually regular
mammography screening starting from age 45 years. Evidence suggested that screening
mammography in women aged 40 to 69 years old is associated with reduced breast cancer
death (Oeffinger et al. 2015). In terms of therapy, breast cancer can be treated by surgery,
radiation therapy, chemotherapy, hormone therapy and targeted therapy. Noticeably, breast
cancer is one of the few cancers can be traced with individualized targeted therapy, which
significantly improved survival rates (Perez 2011). The prognosis of breast cancer is highly
related with the stages of cancer, and the five-year relative survival rate ranges from 100%
for stage 0 to 22% for stage IV, according to the SEER database from National Cancer
Institute (http://seer.cancer.gov/).

1.1.2.2 Risk factors of breast cancer
Like most types of other cancers, the risk of breast cancer includes gender (mostly
women), aging, personal and familial history, ethnicity, dense of breast tissue and genetic
factors (Singletary 2003). About 5-10% of breast cancer are though to be inherited breast
cancer (Hedenfalk et al. 2001). BRCA1 (Breast-cancer susceptibility gene 1) and BRCA2
(Breast-cancer susceptibility gene 2) are two most common causes of hereditary breast
cancer . The average breast cancer risk with BRCA1 mutation is between 55-65% while the
rate for BRCA2 mutations is about 45% (Hedenfalk et al. 2001, Jiang and Greenberg 2015).
Both BRCA1 and BRCA2 function as tumor suppressors and play a central role in
homology-directed DNA damage repair pathway and cell cycle checkpoints (Jiang and
Greenberg 2015). In addition to BRCA genes, changes of many other genes can also lead to
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inherited breast cancers, including ATM, TP53, CHEK2, PTEN,CDH1, STK11, and PALB2.
Noticeably, many of the genes involved in inherited breast cancer have a functions in DNA
damage repair (DDR) pathways. According to TCGA database, most frequently mutated
genes in breast cancer includes both well known oncogenes and tumor suppressor genes,
such as P53 and PTEN.

1.1.2.3 Subtypes of breast cancer
Like all other cancers, breast cancer is a genetic disease. According to the gene
expression profiles, breast cancers can be classified into serval major subgroups: luminal
breast cancer, human epidermal growth factor receptor 2 + (HER2+) breast cancer , and basal
like breast cancer (Perou et al. 2000, Sorlie et al. 2001). Each subtype of breast cancer has
different biological and clinical presentations, including risk factor, strategies of treatment,
and preferential sites of metastasis. Luminal breast cancer, also known as estrogen receptor
(ER)-positive breast cancer, accounts for about two-thirds of breast cancers (Ignatiadis and
Sotiriou 2013). According to the expression profiles, luminal breast cancers can be further
divided into two categories: luminal A breast cancer, in which cancer cells have higher
expression of ER or ER regulated genes; luminal B breast cancer, in which cancer cells have
lower level of ER or ER regulated genes. The luminal B breast cancer usually shows lower
progesterone expression, higher tumor rate, and being more proliferative (Creighton 2012).
The treatment strategy is also highly depends on the subgroup. For example, endocrine
therapy alone is recommended for luminal A type of breast cancer with a high expression of
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ER, while both endocrine and chemotherapy are recommended to luminal B type of breast
cancer ,which is generally more aggressive.
HER2 is a transmembrane receptor belongs to the epidermal growth factor receptor
family. Upon binding to its ligand heregulin, HER2 activates NF-κB a number of
downstream pathways, including PI3K/Akt and Ras/Raf/MAPK signaling (Yarden and
Sliwkowski 2001). It has also been suggested that NF-κB pathways is playing critical role for
HER2-asscociated breast cancer progression (Merkhofer et al. 2010). However, the
molecular mechanism by which HER2-induced NF-κB activation remains undetermined and
controversial. HER2 positive breast cancer cells highly express HER2 due to gene
amplification or enhanced mRNA or protein level. As a result, HER2+ breast cancer cells
have constitutive activated HER2 downstream signaling and are highly proliferative and
resistant to apoptosis. Breast cancers with oncogenic HER2 can be treated by monoclonal
antibody trastuzumab, which binds to the extracellular domain of HER2 receptor (Molina et
al. 2001). The mechanism includes antibody-dependent cell-mediated cytotoxicity (ADCC),
inhibition of the extracellular domain (ECD) of HER2 receptor, inhibition of HER2
dimerization, and internalization of HER2 (Molina et al. 2001, Arteaga et al. 2012). It has
been suggested that combination of trastuzumab and chemotherapy produced a benefit in
disease-free survival (Yin et al. 2011). Even though trastuzumab is a very efficient and
effective way to treat HER2+ breast cancer, like almost all other type of targeted therapy,
cancer cells eventually become resistant to trastuzumab. The mechanisms by which breast
cancer cells become be resistant to trastuzumab includes (1) structural mutation in HER2, (2)
alternative activation of other tyrosine kinase receptors, such as insulin-like growth factor
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receptor and (3) alternation of HER2 downstream pathway molecules (Vu and Claret 2012).
Therefore, identifying new therapeutic target in HER2+ breast cancer will be an urgent task.
The basal-like breast cancer is typically associated with more aggressive behavior and
poor prognosis, and they typically do not express hormone receptors nor HER2 receptor, and
is often named as “triple negative” breast cancer (Rakha et al. 2008). Although majority of
basal-like cancers are triple negative and major of triple negative cancers are basal-like, they
are not interchangeable. The expression profiles and clinical outcome can be very different
between a triple negative breast cancer and a basal-like breast cancer. The histological
definition of basal-like breast cancer includes: (i) lack of ER, PR and HER2 expression, (ii)
expression of one or more of the followings: CD5/6, CK14 and CK17, (iii) lack of ER and
HER2 in conjunction with CD5/6 and/or EGFR; and (iv) lack of ER, PR and HER2 in
conjunction with expression of CD5/6 and EGFR (Nielsen et al. 2004, Cheang et al. 2008,
Badve et al. 2011). The basal-like breast cancer is associated with specific pattern of distal
metastasis with a preference in lung and brain and poorer prognosis (Banerjee et al. 2006,
Fulford et al. 2007). It has been suggested that basal-like breast cancer is associated with
BRCA1 deficiency, as a large majority of breast cancers with BRCA1 mutations have basallike cancer phenotype (Foulkes et al. 2003). Although the reason for the underlying
association between basal-like breast cancer and loss of BRCA1 is not completely clear, it
has been indicated that BRCA1 inactivation plays a role in differentiation of mammary
epithelial cells (Furuta et al. 2005). In terms of cancer treatment, basal-like breast cancer now
can only be treated by chemotherapy other than surgery, since it does not express hormone
receptors nor HER2 receptors.
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1.1.2.4 Mouse models of breast cancer
The biology of breast cancer can be studied in vivo by using mouse models. Although
xenograft model allows investigation on the tumor proliferation and metastasis in vivo, there
are fundamental limitations of this approach. First, since most xenografts are established in
immunodeficient mice such as SCID (severe combined immunodeficiency) mice, the
interaction between tumor cells and immune cells cannot be studied in such models. In fact,
growing number of evidence suggests the immune system is playing a central role in
tumorigenesis and tumor progression in vivo (Schreiber et al. 2011). Second, xenografts are
usually being subcutaneously injected into sides of the body, where the microenvironment is
completely different from the in situ microenvironment. Third, many established tumor cell
lines have already undergone extensive evolution and therefore it is difficult to recapture
early events in tumorigenesis.
In comparison, genetically engineered mice (GEM) are powerful preclinical models
to study breast cancer progression in vivo by manipulating both oncogenes and tumor
suppressor genes specifically in the mammary gland. To achieve this, transgenic mice
carrying breast cancer-causing oncogenes have been generated since late 1980s, such as
Erbb2, PyMT (polyoma virus middle T) and Myc, under transcriptional control of mouse
mammary tumor virus (MMTV) promoter (Sinn et al. 1987, Muller et al. 1988, Guy et al.
1992, Guy et al. 1992). These transgenic mice develop mammary tumors similar to human
breast cancers and undergo spontaneous metastasis (Sinn et al. 1987, Muller et al. 1988, Guy
et al. 1992). In addition, advances in genetic engineering also allow more precise control of
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the timing and developmental context of breast cancer. For example, to study the
contribution of tyrosine kinase c-Src in the development of PyMT-induced breast cancer,
Marcotte et al. crossed the MMTV-PyMT mice with a mammary epithelial cell-specific c-Src
deletion mouse model (c-Srclox/lox; MMTV-Cre) (Marcotte et al. 2012). In this model, authors
demonstrated that c-Src contributes to PyMT-induced breast cancer tumorigenesis by
regulating cell-cycle progression (Marcotte et al. 2012). In summary, transgenic mouse
models for breast cancer closely recapitulate human breast cancer and serve as powerful
preclinical models for scientific investigation.

1.2 The transcription factor NF-κB
1.2.1 Discovery of NF-κB
In 1986, the transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of
activated B cells) was first discovered as a protein complex that binds to the κ light chain
enhancer specifically in the B cells by David Baltimore's group (Sen and Baltimore 1986,
Singh et al. 1986, Staudt et al. 1986, Weinberger et al. 1986, Baltimore 2009). Since NF-κB
specifically binds to κ light chain enhancer, it is crucial to the inducibility of κ enhancer
(Atchison and Perry 1987, Lenardo et al. 1987). Although NF-κB was initially thought to be
specific in B cells, Sen and Baltimore soon discovered that NF-κB also exist in many other
cell types, including Jurkat cells and even HeLa cells (Sen and Baltimore 1986). To further
prove the concept that NF-κB is the transcription factor that responsible for expression of κ
light chain, Sen and Baltimore used the 70Z/3 cells, in which there is no detectable NF-κB
and transcription of the κ gene can be induced by LPS (Parslow and Granner 1982, Sen and
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Baltimore 1986). The hypothesis was that LPS would induce NF-κB. Consistent with this
hypothesis, Sen and Baltimore showed that LPS potently induced NF-κB in 70Z/3 cells,
which clearly demonstrates that NF-κB is responsible for the expression of κ gene (Sen and
Baltimore 1986). To further investigate the activation mechanism of NF-κB, Sen and
Baltimore showed that the induction of NF-κB does not require protein synthesis (Sen and
Baltimore 1986). Furthermore, a combination of LPS and cyclohgeximide which blocks new
protein systhesis causes a superinduction of NF-κB. Based on this data, Sen and Baltimore
suggest that (i) NF-κB pre-exists in the cells and (ii) the induction of NF-κB may be
mediated by posttranslational modification of precursor factor of NF-κB (Sen and Baltimore
1986). Impressive as it is, this notion turns out to be very precise and true even after 20 years
of intensive investigation of NF-κB.
To further investigate the molecular mechanism by which NF-κB is activated,
Baeuerle and Baltimore found that although NF-κB is virtually undetectable in 70Z/3 cells, it
becomes detectable only in the cytosolic fraction after denaturation and renaturation
(Baeuerle and Baltimore 1988). In addition, the authors showed that NF-κB becomes
detectable in the nuclear fraction upon treatment with phorbol esters (Baeuerle and Baltimore
1988). This data indicates that NF-κB pre-exists in an inactive form in the cytosol and is
released to the nucleus upon stimulation. Subsequently, Baeuerle and Baltimore identified a
68kD protein that specifically inhibits NF-κB DNA binding capability, and therefore it is
named as inhibor-κB (IκB) (Baeuerle and Baltimore 1988). Based on this observation, it was
further hypothesized that the activation of NF-κB requires posttranslational modification on
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IκB protein (Baeuerle and Baltimore 1988). It turned out to be exact the case. Together, these
early studies have established most fundamental framework of the NF-κB pathway.

1.2.2 Overview of NF-κB pathway
NF-κB family consists five members, including p65 (RelA), p50, p52, c-Rel and RelB
(Hayden and Ghosh 2012). They share an N-terminal Rel homology domain (RHD), which is
responsible for binding DNA and homo- or heterodimerization with other members (Hayden
and Ghosh 2012). The NF-κB dimers bind to the κB sites of the promoters or enhancers of
the target genes and thereby regulate transcription by recruiting coactivators and repressors.
RelA, c-Rel and RelB positively regulate gene expression through the transcription activation
domain (TAD), while p50 and p52 do not have TAD and therefore they may repress gene
transcription if they are not associated with a TAD-containing NF-κB subunit. However p50
and p52 can still positively regulate transcription if they forms a heterodimer with a TAD
containing NF-κB subunit (Hayden and Ghosh 2012). The NF-κB signaling can be
categorized into two categories according to the activation mechanisms: canonical NF-κB
pathway and noncanonical NF-κB pathway.

1.2.2 Canonical NF-κB pathway
The canonical NF-κB signaling can be triggered by the activation of many kinds of
receptors on immune cells, including antigen receptors, pattern recognition receptors (PRRs)
such as Toll-like receptors (TLRs), TNF receptor (TNFR) and IL-1 receptor (IL-1R) (Hayden
and Ghosh 2012). In the quiescent state, the NF-κB family members are kept in cytosol and
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remains inactive state by associating with IκB proteins. The IκB protein family contains
IκB𝛼, IκB𝛽, IκB𝜀, IκB𝜁, B-cell lymphoma 3 (BCL-3), IκBns, NF-κB1 (also known as p100)
and NF-κB2 (also knowns as p105) (Beg and Baldwin 1993). These IκB proteins are
characterized by containing ankyrin repeat domains (ANK) (Beg and Baldwin 1993). Upon
stimulation, IκB proteins will be rapidly phosphorylated by IκB kinase (IKK) complex. Once
phosphorylated, IκB proteins will be K48-linked ubiquitinated and processed by proteasome
for rapid degradation. The degradation of IκB proteins allows NF-κB subunits to translocate
into the nucleus and initiate transcription. The IKK complex is composed by three different
proteins, IKK𝛽 (also known as IKK2), IKK𝛼 (also known as IKK1) and NF-κB essential
modulator (NEMO), which is also known as IKK𝛾. In canonical NF-κB pathway, the IKK
complex is activated through several distinct mechanism depending on the type of stimuli.
For example, the TNFR-induced NF-κB activation requires the recruitment and
assembly of several death domain (DD)- and caspase recruitment domain (CARD)containing proteins, including TRADD (TNFRSF1A-associated via death domain), TRAF2
(TNF receptor-associated factor 2), RIP1 (receptor interacting protein 1), cIAP1 (cellular
inhibitor of apoptosis protein 1) and cIAP2 (cellular inhibitor of apoptosis protein 2)
(Hayden and Ghosh 2014). Mechanistically, cIAP1 and cIAP2 function as E3 ligase to
trigger ubiquitination of IKK complex (Mahoney et al. 2008). In addition, the linear
ubiquitin chain assembly complex (LUBAC) is also required for TNF-induced IKK
ubiquitination (Haas et al. 2009, Rahighi et al. 2009, Gerlach et al. 2011, Ikeda et al. 2011,
Tokunaga et al. 2011). At the mean time, the ubiquitination of RIP1 recruits TAK1 to
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phosphorylate IKK complex (Takaesu et al. 2003, Sato et al. 2005, Shim et al. 2005, Ea et al.
2006, Li et al. 2006). Both ubiquitination and phosphorylation are required for a complete
activation of IKK (Hayden and Ghosh 2014). In comparison, the toll-like receptors activate
IKK complex through a different mechanism, in which different scaffold proteins are
involved (Kawai and Akira 2007). Upon binding to its ligand, the Toll IL-1R (TIR) domain
of TLR4 recruits other TIR-containing adaptor proteins, such as MyD88 (myeloid
differentiation primary response gene 88) and TICAM1 (TIR domain-containing adaptor
molecule 1) (Medzhitov et al. 1998, Kawai et al. 1999, Yamamoto et al. 2002). Upon
activation TLR4 activation, MyD88 recruits IRAK-4 (IL1-R-associated kinases-4), which
further recruits IL-1R-associated kinases-1 to form IRAK-4:IRAK-1 complex (Kanakaraj et
al. 1998, Li et al. 2002, Suzuki et al. 2002). The IRAK-4:IRAK-1 complex recruits TNF
receptor-associated factor 6 (TRAF6), which further recruits TAK1 to phosphorylate IKK
complex and NF-κB activation (Adhikari et al. 2007).

1.2.3 Non-canonical NF-κB pathway
The discovery of Non-canonical NF-κB pathway originates from the finding that NIK
(NF-κB-inducing kinase) mediates the proteolytic processing of p100 (NF-κB2) to p52 (Xiao
et al. 2001). P100 (NF-κB2) is an IκB-like protein and functions to inhibit RelB translocation
(Solan et al. 2002). After processing to p52, it can induced noncanonical NF-κB activation by
forming heterodimer with RelB (RelB:p52 dimer) (Coope et al. 2002). The noncanonical NFκB signaling is induced by several specific cytokines in the TNF cytokine family, such as
CD40 ligand, B-cell activating factor (BAFF) and lymphotoxin-β (Sun 2011). The hallmark
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of noncanonical is the involvement of IKK𝛼 and NIK rather than phosphorylation of IκB
proteins. For example, upon CD40 binds to its ligand CD40L, TRAF2 is recruited to the
receptor and target TRAF3 for proteasome degradation. Since TRAF3 functions to
destabilize NIK by inducing NIK ubiquitination and degradation, TRAF3 degradation leads
to a stabilization of NIK, which phosphorylates and activates IKK𝛼. The activated IKK𝛼 will
further phosphorylate p100, which binds and keeps NF-κB subunit p52 in the cytosol. Once
phosphorylated, p100 will be targeted by SCF𝛽TRCP complex and release p52 into the nucleus
to initiate transcription by forming heterdimer with RelB (Sun 2011).

1.2.4 The role of NF-κB signaling in inflammation
NF-κB signaling plays a central role in inflammation as it controls a variety of pro
inflammatory cytokines, chemokines and adhesion molecules. Both activation of antigen
receptors and pattern recognition receptors (PPR) lead to NF-κB activation and trigger a
series of immune responses. In addition, many inflammatory cytokines, such as TNF𝛼 and
IL-1, are potent activator of NF-κB (Hayden and Ghosh 2012). Given the importance of NFκB in inflammation, many chronicle inflammatory diseases are associated with aberrant NFκB, such as rheumatoid arthritis, atherosclerosis, chronic obstructive pulmonary disease
(COPD), asthma, multiple sclerosis, inflammatory bowel disease (IBD), and ulcerative colitis
(Tak and Firestein 2001). In addition to production of proinflammatory cytokines, NF-κB
also mediates the expression of anti-apoptotic genes, including cIAP-1 and c-IAP2, which
functions to suppress the activation of caspase-8 (Wang et al. 1998). Therefore, NF-κB plays
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a central role in mediating inflammatory responses by coordinately control immune cells
activation and survival.

1.2.5 The role of NF-κB signaling in hematopoietic malignancies
NF-κB has both direct and indirect impact on human cancers. Mutations affecting
NF-κB pathway are causes for many types of lymphomas. For example, a truncated p100
(NF-κB2) protein was found in rearranged B-cell lymphomas (Neri et al. 1991). The MALT
B cell lymphoma with t(1;14)(p22;q32) translocation involves a recurrent breakpoint
upstream of the promoter of Bcl10, which encodes a protein BCL10 (Willis et al. 1999).
While wild-type BCL10 leads to both NF-κB activation and apoptosis, the truncated form of
BCL10 expressed in MALT lymphoma constitutively activates NF-κB without causing
apoptosis. MALT1 lymphoma with a t(11;18)(q21;q21) genetic translocation also has
constitutive NF-κB activation, which is activated by cIAP2-MALT1 fusion protein created by
t(11;18)(q21;q21) translocation (Levine et al. 1989). Oncogenic NF-κB signaling also plays
a pathogenic role in activated B cell (ABC) type of diffuse large B cell lymphoma (DLBCL),
but not in germinal center B-cell-like (GCB) type of DLBCL (Davis et al. 2001). About 10%
of ABC-DLBCL have mutated CARD11 gene, which encodes for protein CARMA1 (Lenz et
al. 2008). CARMA1 is required for TCR and BCR induced NF-κB activation in
lymphocytes (Wang et al. 2002). Most mutations in CARMA1 in ACB-DLBCL occurs in the
coiled-coil domain and makes CARMA1 a constitutive activator of NF-κB (Lenz et al.
2008).
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Oncogenic NF-κB also plays a fundamental role in the oncogenesis of multiple
myeloma (MM). Annuziata et al. and Keats et al. showed that many MM cell lines and
primary cells from MM patients have mutations in signaling components in NF-κB pathway
(Annunziata et al. 2007, Keats et al. 2007). Several mutations involved in positive regulators
in both canonical and noncanonical pathway have been identified, including CD40, LT𝛽R,
TAC1, NIK, NF-κB1 and NF-κB2 (Annunziata et al. 2007, Keats et al. 2007). In addition,
authors also identified loss of function mutations in negative regulators of NF-κB pathway,
including TRAF2, TRAF3, cIAP-1, cIAP-2 and CYLD (Annunziata et al. 2007, Keats et al.
2007). Mutations in genes encoding those proteins leads to impaired negative regulation of
NF-κB and results enhanced NF-κB activation in MM patients.

1.2.6 The role of NF-κB signaling in solid tumors
NF-κB has also been implicated of playing a positive roles during the onset and
progression of many types of solid tumors. Myelin et al. showed that NF-κB signaling is
required for the progression for oncogenic K-ras (K-rasG12D) induced lung adenocarcinoma in
a genetically engineered mouse model (Meylan et al. 2009). Consistently, Ling et al. showed
that IKK𝛽 (IKK2) is required for oncogenic K-ras (K-rasG12D) induced pancreatic ductal
adenocarcinoma in a transgenic mouse model (Ling et al. 2012). In addition, by using a
systematic RNA interference screening to detect synthetic lethal molecules in K-ras mutant
cell lines, Barbie et al. identified TBK1 as a crucial protein for cell survival in K-ras mutant
cells (Barbie et al. 2009). Mechanistically, TBK1 functions to activate NF-κB signaling in Kras mutant cell lines and suppression of TBK1 results apoptosis in those cell lines (Barbie et
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al. 2009). Together, these lines of investigations proved a critical role of NF-κB signaling in
oncogenic K-ras-associated solid tumor progression.
In addition to K-ras, epidermal growth factor receptor (EGFR) also induces NF-κB
activation in many types of solid tumors. For example, Jiang et al. demonstrated that
CARMA3 is involved in EGFR induced NF-κB activation and contributes to cell
proliferation in A431 cell line (Jiang et al. 2011). In addition, Yang et al. demonstrated that
EGFR-induced NF-κB activation is required for EGFR-associated tumor progression via
upregulation of the expression of pyruvate kinase M2 (PKM2), which plays a central role in
tumor metabolism (Mazurek et al. 2005, Yang et al. 2012). In addition to a direct
involvement of NF-κB signaling in EGFR-associated tumor malignancy, NF-κB activation is
also responsible for drug resistance of EGFR tyrosine kinase inhibitors (TKIs) (Bivona et al.
2011). Through a pooled RNA interference screening, Bivona et al. showed that knockdown
of several component of NF-κB pathway specifically enhanced apoptosis induced by TKI
erlotinib in EGFR-mutant lung cancer cells (Bivona et al. 2011). In addition, overexpression
of several positive regulators in NF-κB pathway rescued EGFR-mutant lung cancer cells
from TKI treatment (Bivona et al. 2011). Therefore, NF-κB can be served as a potential drug
target in combination with EGFR TKIs. In summary, NF-κB is crucial for the tumorigenesis
and development of EGFR-associated cancer. However, the molecular mechanism by which
EGFR activates NF-κB signaling remains to be fully established.
In addition to lung cancer, NF-κB is also playing a crucial role in the tumorigenesis of
breast cancer. Bissau et al. found that activated NF-κB was predominantly found in estrogen
receptor (ER)-negative and heregulin (HRG) receptor HER2-positive primary breast cancer
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samples (Biswas et al. 2004). The authors further demonstrated that HRG activates NF-κB
through HER2 and IKK complex, as inhibition of HER2 and IKK complex blocked HRGinduced NF-κB activation and induced cell apoptosis (Biswas et al. 2004). In addition,
Kendellen et al. showed that both canonical and noncanonical NF-κB signaling promote
breast cancer tumor-initiating cells (TICs) (Kendellen et al. 2014). The authors demonstrated
that both canonical and noncanonical NF-κB signaling are activated in TICs and are required
for their self-renew potential (Kendellen et al. 2014). Consistently, through generating a
transgenic mouse model (MMTV-ErbB2/I𝜅B𝛼SR) in which mammary tumor will be
developed in the absence of NF-κB activation, Liu et al. showed that NF-κB pathway
governs mammary tumorigenesis and stem cell expansion in this mouse model (Liu et al.
2010). Furthermore, NF-κB is also directly involved in mammary tumor migration and
metastasis. Huber et al. showed that IKK-NF-κB signaling axis is required for induction of
epithelial-mesenchymal transition (EMT), which is a fundamental process for cell migration
and metastasis (Huber et al. 2004, Kalluri and Weinberg 2009). In summary, NF-κB
signaling plays a multifunctional roles in the tumorigenesis and development of mammary
tumors, especially in HER2-positive breast cancers. However, the molecular mechanism by
which HER2 activates NF-κB remains to be investigated.

1.3 The biochemical properties and functions of MALT1
1.3.1 The discovery of MALT1
MALT1, also known as paracaspase, was initially identified by Vishva Dixit and his
colleagues in the year of 2000 (Uren et al. 2000). Based on the sequence comparison of
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caspase-like domains from several species, Uren et al. identified two homologs of caspaselike proteins, paracaspase and metacaspase (Uren et al. 2000). To determine the binding
protein of paracaspase, the authors performed a two hybrid screen using the prodomain of
paracaspase as a bait, and they identified BCL10 (B cell lymphoma 10) as a strong
interaction protein with human paracaspase (Uren et al. 2000). This result has been verified
by the authors through a series of biochemical experiments, including in vitro coimmunoprecipitation (co-IP) and colocalization revealed by immunofluorescence experiment
(Uren et al. 2000).
With a further search of paracaspase homologs, Uren et al. further identified that
human paracaspase matched to the sequence of MALT1 (Mucosa Associated Lymphoid
Tissue lymphoma translocation protein 1), which was involved in a t(11;18)(q21;q21) genetic
translocation. The t(11;18)(q21;q21) was initially described in 1989 in two cases of nonHodgkin lymphomas (Levine et al. 1989). Subsequently, this translocation was also reported
in other types of MALT lymphomas by other groups (Griffin et al. 1992, Horsman et al.
1992, Leroux et al. 1993, Auer et al. 1997, Ott et al. 1997). Mechanistically, the t(11;18)
(q21;q21) translocation generates a chimeric protein with a fusion of the N-terminus of
cIAP2 with the C-terminus of paracaspase. The cIAP2-MALT1 transcript contains three
baculovirus IAP repeats (BIRs) from cIAP2 and the caspase-like domain from MALT1. The
fusion protein cIAP2-MALT1 is a potent activator of NF-κB, as overexpression of cIAP2MALT1 resulted an 80-fold to 300-fold of NF-κB induction (Uren et al. 2000).
The full length MALT1 contains a death domain (DD) at its N-terminus, following by
two immunoglobulin domains, and a caspase-like domain at its C-terminus (Figure 1) (Uren

21

et al. 2000). The major function of MALT1 involves in antigen receptor signaling in
lymphocytes and lymphocytes activation. In 2003, MALT1 deficient transgenic mice were
independently generate by two groups (Ruefli-Brasse et al. 2003, Ruland et al. 2003) . Both
groups showed a clear defect on TCR-induced NF-κB activation in T cells isolated from
MALT1 deficient mice (Ruefli-Brasse et al. 2003, Ruland et al. 2003). In addition, both
groups showed a defect of JNK activation and IL-2 production in MALT1 deficient T cells.
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Figure 1. Structural basis of MALT1, cIAP2 and cIAP-MALT1 fusion protein.
MALT1 contains one death domain (DD), two immunoglobulin (Ig) domains and one
caspase-like domain at its C-terminus followed by another Ig-like domain. cIAP2 consists of
three baculovirus IAP repeats (BIRs), a caspase associated recruitment domain (CARD) and
a really interesting new gene (RING) domain. The fusion protein cIAP2-MALT1 is
composed of three BIR domains from the N-terminal of cIAP2 and the caspase-like domain
from the C-terminus of MALT1.
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1.3.2 The function of CARMA1-BCL10-MALT1 (CBM) complex in lymphocytes
In response to TCR activation, MALT1 forms a complex with two scaffold protein,
CARD11 (Caspase recruitment domain-containing protein 11), also known as CARMA1
(CARD-containing MAGUK protein 1), and BCL10 (B-cell lymphoma/leukemia 10)
(Blonska and Lin 2009).

In 2002, several groups independently identified that

CARMA1 is required for TCR-induced NF-κB activation and it is an interacting partner with
BCL10 upon TCR stimulation (Gaide et al. 2002, Pomerantz et al. 2002, Wang et al. 2002).
CARMA1 is phosphorylated by PKC (protein kinase C) upon TCR stimulation (Matsumoto
et al. 2005, Sommer et al. 2005, Shambharkar et al. 2007). Phosphorylation of CARMA1
triggers its conformational change and exposes its CARD domain, which rapidly recruits
BCL10 and MALT1 to form the CARMA1-BCL10-MALT1 complex, also known as the
CBM complex (Matsumoto et al. 2005, Sommer et al. 2005, Shambharkar et al. 2007). The
activated CBM complex presents in a highly polymerized structure and is able to recruit
downstream factors such as E3 ubiquitin ligase TRAF6 to activate the IKK complex (Sun et
al. 2004, Qiao et al. 2013). It is proposed that both TRAF6-mediated ubiquitination and
TAK1-mediated phosphorylation are required to a full activation of the IKK complex (Figure
2A) (Sun et al. 2004).
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Figure 2. The CARMA1-BCL10-MALT1 complex mediated NF-κB activation and
structural basis of CARMA protein family members.
(A) Molecular mechanism by which TCR induces NF-κB activation. TCR activates
CARMA1 through PKC𝜃-dependent phosphorylation in the linker region in CARMA1. The
activated CARMA1 recruits MALT1 and BCL10 to form the CARMA1-BCL10-MALT1
complex, which further recruits E3 ligase such as TRAF6 to mediate IKK𝛾 ubiquitination. At
the mean time, TAK1 phosphorylates IKK𝛽 to fully activates IKK complex. The activated
IKK complex phosphorylates I𝜅B𝛼, which will undergo ubiquitination and proteasome
degradation. (B) The structural basis of CARMA protein family members. CARMA1,
CARMA2 and CARMA3 are composed by a CARD domain and a coil-coiled (C-C) domain
at the N-terminus, and a membrane associated guanylate kinase (MAGUK) domain at this C-
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terminus. The MAGUK domain includes a PDZ domain, a SH3 domain and a GUK domain.
In comparison, CARD9 only contains the N-terminal CARD and C-C domain.
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1.3.3 The function of CBM complex in other cell types
In addition to TCR and BCR mediated NF-κB, the CBM complex is also involved in
NF-κB activation in response to many types of stimuli in a variety of cells (Blonska and Lin
2011). Based on the similarity of sequences and structure, the CARMA protein family
consists CARMA1, CARMA2, CARMA3 and CARD9 (Figure 2B), which lacks the
MAGUK domain. Among them, CARMA1 is primarily expressed in hematopoietic tissue;
CARMA2 is expressed in placenta; CARMA3 is expressed in most non-hematopoietic cells;
CARD9 is only expressed in myeloid cells. It has been shown CARMA1, CARMA3 and
CARD9 functions similarly in terms of forming the CBM complex to mediate NF-κB
activation. In addition to lymphocytes, CARMA1-BCL10-MALT1 complex also mediates
the immunoreceptor tyrosine-based activation motif (ITAM)-coupled natural killer (NK) cells
receptors-induced NF-κB activation (Gross et al. 2008). The CARD9-BCL10-MALT1
complex is required for c-type lectin receptors, including Dectin-1, Dectin-2 and Dectin-3,
induced NF-κB activation in myeloid cells, such as macrophages and dendritic cells (Bertin
et al. 2000, Gross et al. 2006, Hara et al. 2007, Hsu et al. 2007, Bi et al. 2010, Zhao et al.
2014). It has been also reported that CARD9 is essential for the activation of myeloid cells
through ITAM associated receptors (Hara et al. 2007). In non-hematopoietic cells,
CARMA3-BCL10-MALT1 complex is required for G protein-coupled receptors (GPCR)induced NF-κB activation, as CARMA3- and BCL10-deficient cells are defective for
lysophosphatidic acid (LPA)-mediated NF-κB activation (Grabiner et al. 2007). Similar
observations suggesting a requirement of CBM complex in GPCR-induced NF-κB activation
have been reported independently from other groups (Klemm et al. 2007, Wang et al. 2007,
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McAllister-Lucas et al. 2010). In addition to GPCR, recently Jiang et al. showed that
CARMA3 is required for epidermal growth factor receptor (EGFR)-mediated NF-κB
activation, as CARMA3-deficient cells are defective to epidermal growth factor (EGF)induced NF-κB activation (Jiang et al. 2011). Mechanistically, it is believed that CARMA3BCL10-MALT1 complex in non-hematopoietic cells functions similar to CARMA1-BCL10MALT1 in lymphocytes in a PKC dependent manner, as both GPCR and EGFR activation
cause the activation of PKC. Yet there is no evidence suggesting that PKC directly activates
CARMA3.

1.4 The proteolytic function of MALT1
1.4.1 MALT1 cleaves BCL10 to regulate T-cell adhesion
Although MALT1 is thought to operate as a protease-like caspase based on their
sequence similarity, it was not until 2008 that MALT1 has been demonstrated to contain
protease activity in mammalian cells for the first time. Initially, Lucas et al. showed that a
mutation on a critical cystine residue (C453→A) on the putative catalytic domain only
resulted a modest reduction in NF-κB activity, indicating that the protease activity of MALT1
is dispensable for the NF-κB activation, which is thought to be the major function of MALT1
at that time (Lucas et al. 2001). Two milestone studies published in 2008 by Rebeaud et al.
and Coornaert et al. clearly demonstrated that MALT1 contains protease activity and the
protease activity contributes to T cell activation and NF-κB activation (Coornaert et al. 2008,
Rebeaud et al. 2008). Rebeaud et al. found that MALT1 cleaves its binding partner BCL10 at
the Arg288 site upon stimulation with either PMA/Ionomycin or CD3/CD28 in a number of
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lymphoma and leukemia cell lines (Rebeaud et al. 2008). In addition, the authors proved a
protease activity of MALT1 in vitro by incubating of purified MALT1 with a Bcl-10-derived
fluorogenic peptide substrate (Leu-Arg-Ser-Arg) mimicking the Bcl-10 cleavage site
(Rebeaud et al. 2008). The authors further demonstrated that MALT1 dependent BCL10
cleavage regulates adhesion of T cells to fibronectin but not NF-κB activation (Rebeaud et al.
2008). However, the mechanism by which the processed BCL10 regulates cell adhesion
remains unclear.

1.4.2 MALT1 cleaves A20 to regulate NF-κB activation
Coornaert et al. showed that TCR stimulation results in cleavage of A20 (also known
as Tnfaip3) at the Arg228 site in a MALT1 dependent manner in Jurkat cells and primary
human T cells (Coornaert et al. 2008). A20 is a zinc finger protein which is involved in
negatively regulates inflammatory genes by down regulating NF-κB activity in response to a
variety of stimuli in immune cells (Lee et al. 2000). Through proteolytic cleavage, MALT1
enhances NF-κB activity by generating two inactive A20 fragments in the Jurkat cells
(Coornaert et al. 2008). By generating mutations on A20 and performing in vitro cleavage
assay, the authors further demonstrated that MALT1 is an arginine specific protease
(Rebeaud et al. 2008). This is consistent with the cleavage site on both human and mouse
BCL10 (Rebeaud et al. 2008). In fact, arginine specific cleavage applies to all subsequently
identified substrates for MALT1.

1.4.3 MALT1 cleaves CYLD to regulate JNK activation
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Similar to A20, the ubiquitin-specific-processing protease CYLD is also involved in
negative regulation of a variety of signaling pathways, including NF-κB (Kovalenko et al.
2003, Trompouki et al. 2003), Jun amino-terminal kinases (JNK) (Reiley et al. 2007), and
transforming growth factor-𝛽 (TGF-𝛽) signaling (Lim et al. 2012). Staal et al. showed that
CYLD is cleaved into two fragments upon TCR stimulation in Jurkat cells, and upon BCR
stimulation in SSK41 and Raji cells, respectively (Staal et al. 2011). In addition, MALT1
proteolytic activity is required for such cleavage, as demonstrated by treating cells with small
peptide inhibitor z-VRPR-Fmk, which can specifically block the proteolytic activity of
MALT1 (Rebeaud et al. 2008, Staal et al. 2011). Consistent with previous notion that MALT1
is a arginine specific protease, MALT1 processes both human and mouse CYLD at the
Arg324 site, as a (R324→A) CYLD mutant is not cleavable by MALT1 (Staal et al. 2011).
Interestingly, MALT1 dependent CYLD cleavage regulates JNK pathways instead of NF-κB.
Steal et al. shows that MALT1 enhances JNK activation by cleaving and inactivating CYLD
(Staal et al. 2011). Therefore, MALT1 proteolytic activity is a positive regulator in multiple
pathways downstream of TCR signaling.

1.4.4 MALT1 cleaves RelB to regulate NF-κB activation
RelB is a member of the NF-κB transcription factors. It has been suggested that RelB
plays a negative roles in T cell activation and inflammation, as RelB-deficient mice display a
multiorgan inflammation phenotype (Weih et al. 1995). Hailfinger et al. showed that MALT1
cleaves RelB at Arg85 upon either PMA/Ionomycin stimulation or CD3/CD28 stimulation in
Jurkat cells and murine primary T cells (Hailfinger et al. 2011). RelB cleavage induces its
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proteasomal degradation and enhances the DNA binding activity of RelA or c-Rel containing
NF-κB heterodimers (Hailfinger et al. 2011). Hailfinger et al. shows that the RelB mutant
(Arg85→G) is resistant to MALT1 dependent cleavage and inhibit the expression of NF-κB
target gene Il2 (Hailfinger et al. 2011). The authors further demonstrated that RelB is
constantly processed by MALT1 in activated B-cell (ABC) type of diffuse large B cell
lymphoma (DLBCL) cells, in which MALT1 is constitutively activated (Ferch et al. 2009,
Hailfinger et al. 2009). RelB processing optimizes the proliferation and survival potential of
ABC-DLBCL as RelB overexpression impairs the survival of ABC-DLBCL cell lines
(Hailfinger et al. 2011). An independent study also suggests that there is excessively higher
level of RelB in MALT1-deficient T cells compared with wild-type controls (Brustle et al.
2012). In addition, the physiological role of MALT1 dependent RelB cleavage is also linked
to the differentiation of functional Th17 cells, although the exact mechanism is not clear yet
(Brustle et al. 2012). Together, these studies demonstrate that MALT1 regulates NF-κB
activation by proteolytically process negative regulator RelB.

1.4.5 MALT1 cleaves HOIL-1 to regulate NF-κB activation
The linear ubiquitin assembly complex (LUBAC) includes HOIL-1 (heme-oxidized
IRP2 ubiquitin ligase 1), HOIP (HOIL-1-interacting protein) and SHARPIN (SHANK
associated RH domain interactor) (Kirisako et al. 2006, Gerlach et al. 2011). LUBAC is the
only E3 ligase complex that generates a linear form of ubiquitination, in which C-terminal
glycine is directly linked to the N-terminal methionine of another ubiquitin (Kirisako et al.
2006). The linear form of ubiquitination plays a critical role in NEMO ubiquitination and
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subsequent NF-κB activation (Tokunaga et al. 2009). Using a 10-plex tandem mass tag
TAILS N-terminal peptide proteomic approaches, Klein et al. attempted to systematically
identify substrates of MALT1 upon T cell activation (Klein et al. 2015). The authors
demonstrate that MATL1 cleaves and inactivates HOIL-1 in the LUBAC complex to reduce
linear ubiquitination and NF-κB activation (Klein et al. 2015). MALT1 processes HOIL-1 at
the site Gly166 upon PMA/Ionomycin stimulation in vitro and in vivo (Klein et al. 2015).
This study provides first evidence that MALT1 is involved in negative regulation of NF-κB
activation (Klein et al. 2015).

1.4.6 MALT1 cleaves Regnase-1 to regulate mRNA stability
Regnase-1, also known as zinc finger CCCH-type containing 12A (Zc3h12a) or
MCP-induced protein 1 (MCPIP1), is a novel ribonuclease (RNase) that is involving in
regulating cytosine stabilities during TLR activation (Matsushita et al. 2009). Generation of
Zc3h12a deficient mice resulted an embryonic lethality at day 12 with an early onset of fetal
autoimmune disease, suggesting that regnase-1 plays a critical role in negative regulation of
inflammatory responses (Matsushita et al. 2009). Mice with a conditional depletion of
regnase-1 in CD4-positive T cells (CD4-Cre; Reg1fl/fl) show autoimmune inflammatory
disease, suggesting regnase-1 also plays a negative role in regulation of T cell activation
(Uehata et al. 2013). Indeed, upon TCR stimulation, a set of cytokine RNA is stabilized in
regnase-1-deficient T cells compared with wild-type controls, suggesting regnase-1
negatively regulates RNA stability in response to stimulation in T cells (Uehata et al. 2013).
Interestingly, TCR stimulation leads to MALT1 dependent cleavage regnase-1 at the site
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Arg111 (Uehata et al. 2013). The cleavage of regnase-1 leads to its inactivation, and thereby
stabilizing its target RNAs, including c-Rel, Ox40, Il2 and I𝜅B𝛼 (Uehata et al. 2013). In
summary, Uehata et al. provides the first evidence suggesting that MALT1 protease activity
controls T cell activation by regulating inflammatory genes at the RNA level (Uehata et al.
2013).

1.4.7 MALT1 cleaves Roquin to regulate mRNA stability
Roquin is a CCCH-type zinc finger protein that regulates target mRNA level via
binding to the constitutive decay element (CDE) region in the 3’ UTR to trigger mRNA
decay (Leppek et al. 2013). Roquin regulates a variety of coding mRNA, including Icos
mRNA, Tnfrsf4 mRNA, and Tnf mRNA (Yu et al. 2007, Glasmacher et al. 2010, Leppek et
al. 2013, Vogel et al. 2013). Jeltsch et al. shows an inflammatory phenotypes in lungs with
enhanced T helper cell 17 (Th17) differentiation in mice lacking roquin expression in CD4+
T cells (Jeltsch et al. 2014). Furthermore, the authors shows that both roquin-1 and roquin-2
were cleaved by MALT1 upon either PMA/Ionomycin or CD3/CD28 stimulation, indicating
Roquin is processed upon T cell activation (Jeltsch et al. 2014). MALT1 preferentially
cleaves both human and mouse roquin-1 at the site Arg510 and roquin-2 at the site Arg509.
The cleavage of roquin-1 and roquin-2 leads to an impaired activity in destabilizing targeting
mRNA involved in Th17 differentiation, including IL-6, ICOS, c-Rel, IRF4, IκBNS and IκBζ
(Jeltsch et al. 2014). Thus, MALT1 promotes Th17 differentiation by negatively regulating
roquin-1 and roquin-2 through proteolytic inactivation.
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1.4.8 Phenotypes of MALT1 deficient and mutant mice
In 2003, two group independently generated MALT1 deficient transgenic mice by
disruption Malt1 exons through homologous recombination in embryonic stem cells (RuefliBrasse et al. 2003, Ruland et al. 2003). Ruefli-Brasse et al. showed that MALT1 is essential
to both T cell and B cell activation through regulating NF-κB activation (Ruefli-Brasse et al.
2003). However, Ruland et al. demonstrated that while MALT1 is absolutely required for T
cell activation and NF-κB activation in response to CD3/CD28 stimulation in T cells,
MALT1 is not required for B cell activation nor NF-κB activation in B cells (Ruland et al.
2003). The underlying reason for this discrepancy remains to be determined.
In 2014, three independent groups reported the generation of protease defective
mutant form of MALT1 knock-in mice (Gewies et al. 2014, Jaworski et al. 2014, Bornancin
et al. 2015). Consistent with all previous findings, the activation of T cells from MALT1
protease deficient mutant mice are significantly impaired compared with controls (Gewies et
al. 2014, Jaworski et al. 2014, Bornancin et al. 2015). This observation confirmed an
essential role of MALT1 protease activity in T cell activation in vivo. Surprisingly, all three
groups consistently show that MALT1 protease deficient knock-in mice display severe
autoimmune phenotypes with multiorgan inflammation (Gewies et al. 2014, Jaworski et al.
2014, Bornancin et al. 2015). Jaworski et al. and Bornancin et al. suggest that this
autoimmune phenotypes are linked to an impairment of regulatory T helper cell (Treg)
development in MALT1 protease deficient knock-in mice, as reconstitution of wild-type Treg
partially rescued the autoimmune phenotypes (Jaworski et al. 2014, Bornancin et al. 2015).
However, the molecular mechanism by which MALT1 regulates the development of natural
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Treg (nTreg) remains to be determined. On the other hand, Gweies et al. suggest that the
autoimmune-like diseases in MALT1 protease-deficient mice are linked to an impairment of
regnase-1 and roquin dependent down-regulation of interferon γ (INFγ), which was found
excessively higher in MALT1 protease-deficient mutant T cells compared with controls
(Gewies et al. 2014). In summary, the underlying causes for the autoimmune phenotypes in
MALT1 protease deficient mice could be complicated and remain to be further investigated.

1.4.9 MALT1 as a therapeutic target in ABC-DLBCL
The protease activity of MALT1 plays a critical role in lymphocytes activation by
cleaving a number of substrates (Figure 3). Consequently, the protease activity also
contributes to certain types of lymphoma. Lymphoma can be categorized into Hodgkin
lymphoma (HL) and non-Hodgkin lymphoma (NHL). Diffuse large B cell lymphoma
(DLBCL) is the most common type of NHL. According to the gene expression profiles,
DLBCL can be classified into two subgroups, activated B cell-like (ABC) type of DLBCL
and germinal center B cell-like (GCB) type of DLBCL (Alizadeh et al. 2000). In 2006,
through a shRNA based screening approach, Ngo et al. identifies that CARD11 and MALT1
shRNAs are selective toxic to ABC type of DLBCL, suggesting a requirement of CARMA1
and MALT1 for ABC-DLBCL survival (Ngo et al. 2006). Subsequently, Hailfinger et al.
show that the protease activity of MALT1 is constitutively activated in ABC-DLBCL but not
GCB-DLBCL cell lines (Hailfinger et al. 2009). Based on this finding, the authors further
treat ACB-DLBCL with MALT1 peptide inhibitor, z-VRPR-Fmk, which specifically blocks
the protease activity in vitro. Treatment with z-VRPR-Fmk significantly inhibits NF-κB
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activation and induced cell apoptosis specifically in ABC-DLBCL (Hailfinger et al. 2009).
Together, Halfinger et al. has provided the first evidence suggesting MALT1 protease activity
is a promising drug target to treat ABC-DLBCL. In addition, Ferch et al. verifies the finding
by Halfinger et al. and suggests that inhibition of MALT1 protease activity is selectively
toxic to ABC-DLBCL (Ferch et al. 2009). Although inhibition MALT1 with v-VRPR-Fmk
induces cell apoptosis in ABC-DLBCL, the efficacy of small peptide inhibition is relatively
low. In 2012, two groups independently identify small molecules inhibitors, MI-2 and
derivatives of active phenothiazines, which work specifically to inhibit the protease activity
of MALT1 in vitro and in vivo. Both inhibitors work potently in inhibiting NF-κB activation
and induce cell apoptosis in ABC-DLBCL (Fontan et al. 2012, Nagel et al. 2012). These
studies provide opportunities to treat ABC-DLBCL by using MALT1 inhibitors.
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Figure 3. The substrates of MALT1.
MALT1 cleaves a number of substrates involving several biological pathways. MALT1
cleaves BCL10 to regulate the stability of intergrin and T cell adhesion. MALT1 cleaves and
inactivates CYLD to upregulate JNK signaling. MALT1 also cleaves HOIL1 (positive
regulator of NF-κB pathway), RelB (negative regulator of NF-κB pathway) and A20
(negative regulator of NF-κB pathway) to enhance NF-κB activation. MALT1 cleaves
ribonuclease Regnase-1, Roquin-1 and Roquin-2 to enhance the stability of many cytokines
at the RNA level to optimize lymphocytes activation and inflammation response.
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CHAPTER 2: THE ROLE OF MALT1 IN EGFR-INDUCED NF-κB ACTIVATION
AND EGFR-ASSOCIATED LUNG CANCER PROGRESSION
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activation and contributes to EGFR-driven lung cancer progression. Oncogene advance
online publication 18 May 2015; doi: 10.1038/onc.2015.146”

Permission of the copyright by the publisher of Nature Publishing Group:
• If you are the author of this content (or his/her designated agent) please read the following.
Since 2003, ownership of copyright in in original research articles remains with the
Authors*, and provided that, when reproducing the Contribution or extracts from it, the
Authors acknowledge first and reference publication in the Journal, the Authors retain the
following non-exclusive rights:
• To reproduce the Contribution in whole or in part in any printed volume (book or thesis) of
which they are the author(s).
• They and any academic institution where they work at the time may reproduce the
Contribution for the purpose of course teaching.
• To reuse figures or tables created by them and contained in the Contribution in other works
created by them.

38

2.1 Introduction
2.1.1 MALT1 is a therapeutic target in lymphoma
MALT1 is an upstream signaling component of NF-κB with high therapeutic
potential. MALT1 has been shown to be a key mediator in NF-κB activation in lymphocytes,
and is required for lymphocyte activation and survival through TCR and BCR signaling
(Thome 2008). Activation of these receptors leads to the activation of protein kinase C,
which phosphorylates the Caspase recruitment domain and membrane-associated guanylate
kinase-like domain (CARMA) family proteins such as CARMA1 in lymphocytes (Sun et al.
2000, Wang et al. 2002). Phosphorylation of the CARMA protein triggers a conformational
change and further recruits MALT1 and B-cell lymphoma protein 10 (BCL10), resulting in
the assembly of the CARMA–BCL10–MALT1 (CBM) complex (Matsumoto et al. 2005,
Sommer et al. 2005). The CBM complex activates the IκB kinase to trigger NF-κB activation
(Blonska and Lin 2011). MALT1 is considered a critical component in constitutive NF-κB
activation in certain types of lymphoma. In MALT lymphoma-associated with the genetic
translocation t(11;18)(q21;21), a cIAP2 (cellular inhibitor of apoptosis 2)-MALT1 fusion
protein gives constitutive NF-κB signals (Akagi et al. 1999, Dierlamm et al. 1999). In
activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL), MALT1 also has a
tumor-promotive role by bridging the constitutive BCR signaling to a dysregulated NF-κB
activity (Ngo et al. 2006).
The therapeutic value of MALT1 is associated with the protein’s caspase-like domain,
which contains an arginine-specific protease activity. The protease activity of MALT1
facilitates optimal NF-κB and AP-1 activation by cleaving negative regulators, such as A20,
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CYLD and RelB (Coornaert et al. 2008, Hailfinger et al. 2011, Staal et al. 2011). In MALT1
lymphoma, the protease activity of the cIAP2–MALT1 fusion protein cleaves and stabilizes
NF-κB-inducing kinase (NIK), resulting in a constitutive NF-κB activity, enhanced adhesion
and resistance to apoptosis (Rosebeck et al. 2011). In addition, several independent studies of
therapeutic applications of MALT1 protease inhibitors in ABC-DLBCL indicated that
MALT1 inhibitors are selectively toxic to this type of lymphoma (Ferch et al. 2009,
Hailfinger et al. 2009, Nagel et al. 2012). These results suggest that MALT1 inhibitors can
potentially serve as therapeutic reagents for certain types of lymphoma. However, the tumorpromotive role of MALT1 has been confirmed only for the lymphoid system. As NF-κB
contributes to tumor malignancy in a wide range of cell types, the oncogenic role and
therapeutic potential of MALT1 need to be investigated in a nonhematopoietic system, such
as solid tumors of epithelial origin. To date, no study has demonstrated a functional role of
MALT1 in solid-tumor progression.

2.1.2 NF-κB signaling in EGFR associated-cancer
One of the most frequently mutated and overexpressed genes in solid tumors is the epidermal
growth factor receptor (EGFR). EGFR overexpression and gain-of-function mutations are
observed in nearly 30% of solid tumors, such as breast cancer, head-and-neck cancer and
non-small-cell lung cancer (NSCLC) (Sharma et al. 2007). EGFR-mediated signaling
contributes to many important malignant properties of tumors, such as cell growth,
proliferation and metabolism. Recently, several groups including ours showed that in
addition to its role in the phosphatidylinositide 3-kinase/Akt and MAPK/ERK (mitogen-
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activated protein kinase–extracellular signal-regulated kinase) pathways, EGFR-induced NFκB activation has an essential role in malignant properties such as proliferation, survival,
migration and metabolism (Jiang et al. 2011, Yang et al. 2012, Pan and Lin 2013). However,
the exact molecular mechanism by which EGFR activates NF-κB remains unclear. In
addition, a physiological role of NF-κB signaling in EGFR-associated tumor has not been
demonstrated so far.

2.1.3 Specific aims and hypothesis
The goal of this study aims to investigate the roles of MALT1 and its protease activity in
solid tumor. Given CARMA3 is required for EGFR-induced NF-κB activation and MALT1 is
an inducible binding partner with CARMA1 in lymphocytes (Che et al. 2004, Jiang et al.
2011), we hypothesize that MALT1 is required for EGFR-induced NF-κB activation and
involved in EGFR-associated cancer progression. To address this hypothesis, we propose to
examine the followings. First, we would like to investigate whether MALT1 mediates EGFRinduced NF-κB activation in human cancer cell lines. Second, we would like to examine
whether the protease activity of MALT1 is required for EGFR-induced NF-κB activation in
human cancer cell lines. Third, we would like to determine whether MALT1 contributes to
EGFR-associated malignant phenotypes, such as proliferation, survival and migration.
Finally, we would like to establish a mouse model in which we will be able to investigate a
role of MALT1 in EGFR-associated lung cancer progression in vivo.
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2.2 Materials and methods
2.2.1 Antibodies and reagents
Phosphorylation-specific antibodies to ERK1/2 (9101) and IκBα (9246) were purchased from
Cell Signaling Technology (Danvers, MA, USA). Antibodies against phosphorylated EGFR
(sc-12351), IκBα (sc-371), lamin B (sc-6216), ERK (sc-154), IKKγ (FL-419) and actin
(sc-8432) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Monoclonal
antibodies against the C terminus of MALT1 were generated in the Genentech (South San
Francisco, CA, USA) central production facility. DNA-oligo probes for NF-κB (E3291) and
Oct-1 (E3241) were purchased from Promega (Madison, WI, USA). Recombinant human
EGF was purchased from Sigma-Aldrich (St Louis, MO, USA). PMA (16561-29-8) and
ionomycin (56092-82-1) were purchased from Fisher Scientific (Pittsburgh, PA, USA). IL-6neutralizing antibodies were purchased from Abcam, Cambridge, MA, USA (ab6672) and
used at 1:400 dilution. TNFα was purchased from Thermo Fisher Scientific (Rockford, IL,
USA). MALT1 protease inhibitor z-VRPR-Fmk was purchased from Enzo Life Sciences, Inc.
(Farmingdale, NY, USA).

2.2.2 Cell cultures
Human A431 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
containing 10% fetal bovine serum (FBS). HCC827 cells were cultured with RPMI medium
containing 10% FBS. Primary MEFs were isolated at E13.5 and cultured with DMEM–10%
FBS. All cells were maintained at 37 °C with 5% CO2.
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2.2.3 Immunoblotting (IB)
The procedure for immunoblotting has been described elsewhere (Grabiner et al. 2007).
Briefly, one million of cells were lysed in 100𝜇l of lysis buffer (150 mM NaCl, 50 mM
HEPES at pH 7.4, 1 mM EDTA, 1% NP-40, protease inhibitors) for 10 minutes. The cell
lysates will be purified by spinning 13,000 r.p.m. for 10 minutes and resulting supernatants
will be saved for western blot analysis. 10-12𝜇l of the resulting supernatant were loaded to
10% of SDS-PAGE and probed with antibodies.

2.2.4 Immunoprecipiation assay
Generally five million of cells were lysed in 300𝜇l of lysis buffer (150 mM NaCl, 50 mM
HEPES at pH 7.4, 1 mM EDTA, 1% NP-40, protease inhibitors) for 10 minutes. The cell
lysates will be purified by spinning 13,000 r.p.m. for 10 minutes and resulting supernatants
will be saved for Immunoprecipiation assay. 30𝜇l of the protein lysis will be saved for
western blot analysis as input. The rest lysis will be incubated together with indicated
antibodies and protein A or protein G agarose beads for overnight at 4 degree. After
incubation, the beads will be washed three times with lysis buffer and will be suspended in
30𝜇l of lysis buffer containing SDS for western blot analysis.

2.2.5 Electrophoretic mobility shift assay (EMSA)
For the electrophoretic mobility shift assay, two million cells were starved overnight in
DMEM containing 0.5% serum and stimulated with reagents, and nuclear extracts were
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isolated. Nuclear extracts (5 µg) were incubated with 1 × 105 c.p.m. of 32P-labeled probes at
room temperature for 15 min. The samples were separated on a native Tris-borate-EDTA
polyacrylamide gel and analyzed by autoradiography.

2.2.6 Gene silencing and reconstitution
Lentivirus vectors were generated by cotransfection of HEK293T cells with plasmids
encoding short hairpin RNA (target sequence for MALT1: 5′CCTCACTACCAGTGGTTCAAA-3′; TRAF6: 5'-GCCACGGGAAATATGTAATATCT-3'):
pCMV-VSV-G (Addgene #8454) and pCMV-dR8.2 (Addgene #8455). The complementary
DNA of human MALT1 was amplified by using pcDNA3-MALT1 as a template and cloned
into the pBabe-hygro (Addgene #1765) vector. The C464A mutation was introduced via sitedirected mutagenesis. To reconstitute MALT1 in A431 cells with a MALT1 knockdown, six
synonymous mutations in the short hairpin RNA-targeting sequence were introduced by PCR
(5′-CCTCACTACCAGTGGTTCAAA-3′ to 5′-CCGCATTATCAATGGTTTAAG-3′), so that
the short hairpin RNA targeted only endogenous MALT1. To produce retrovirus vectors for
infecting MEF, pBabe-human MALT1 was cotransfected with pCL-Eco (Addgene #12371).

2.2.7 MTT Assay
HCC827 cells were seeded in wells of a 96-well plate in 100𝜇l of complete DMEM media.
At the indicated time, 10𝜇l of MTT reagent (5mg/ml) was added to the cells. After 3 hours of

44

incubation, the media containing MTT was removed and metabolized MTT will be dissolved
in 100𝜇l of DMSO. The absorbance was measured at 570nm and was recorded accordingly.

2.2.8 Colony formation assay
Cells were mixed with agarose to a final concentration of 0.6% in complete medium, with or
without EGF (1 ng/ml). Three weeks after culturing, the numbers and sizes of colonies were
determined by inverted microscopy. Nine to ten fields were randomly selected and the size of
each colony visualized was determined.

2.2.9 Migration Assay
A431 and HCC827 cells are subjected to transwell migration assay. 1 × 105 cells were
suspended in 200𝜇l of serum-free DMEM and seeded to BD Faclon cell culture inserts. The
inserts will be placed in a well on a 6-well plate filled with 500𝜇l of complete DMEM to let
the cell migrate to the bottom part of insert. 20 hours after seeding, the insert will be washed
with PBS for twice and will be fixed with 4% paraformaldehyde for 30 minutes. After fixing,
the top layer of inserts (unmigrated cells) will be removed and the inserts will be stained with
crystal violet cell staining solution (0.05% weight/volume) for 5 minutes. The resulting
stained inserts with be photographed and migrated cell will be quantified by reverse
microscopy.

2.2.10 Wound healing assay
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Confluent A431 cells were cultured in serum-free DMEM, and a uniform wound was made
with a p200 pipette tip. Wounded monolayer cells were washed two or three times to remove
detached cells. The initial size of the wound was determined by inverted microscopy
immediately after the wash. After 16–20 h of incubation in serum-free medium, the size of
the wound was analyzed again. Wound closure was calculated as the percentage of the initial
wound area remaining.

2.2.11 Lung metastasis model
To establish a lung metastasis model, three million A431 cells were washed with phosphatebuffered saline, resuspended in 300 µl of serum-free DMEM, and intravenously injected into
the tail veins of SCID mice. Three weeks after injection, mice were killed and the lungs were
fixed by Bouin’s solution (Sigma-Aldrich, #HT10132), so that a metastasis site could be
visualized as a white spot on a yellow background. Metastasis sites on each lung lobe were
counted. Student’s t-test was used to determine statistical significance.

2.2.12 Mouse strains and models
To establish EGFR-induced lung cancer model, tetO-EGFRL858R mice,40 CCSP-rTTA
mice41 and Malt1−/− mice (Ruefli-Brasse et al. 2003) were intercrossed to generate control
mice (tetO-EGFRL858R; CCSP-rTTA; Malt1+/−) and experimental mice (tetO-EGFRL858R;
CCSP-rTTA; Malt1−/−). After weaning, mice were administrated with doxycycline (Alfa
Aesar, Ward Hill, MA, USA) containing water (2 mg/ml) for 2 months. For activating K-rasinduced lung caner model, we crossed LSL-K-rasG12D (Jackson et al. 2001); CCSP-Cre (Li et
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al. 2008) mice and Malt1−/− mice to generate control mice (LSL-K-rasG12D; CCSP-Cre;
Malt1+/−) and experimental mice (LSL-K-rasG12D; CCSP-Cre; Malt1−/−). These mouse strains
were genotyped by PCR as previously described (Fisher et al. 2001, Jackson et al. 2001,
Politi et al. 2006, Li et al. 2008). All animal experiments and procedures were conducted
under the protocol and was approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Texas MD Anderson Cancer Center.

2.2.13 Histology and Immunohistochemical staining
Mouse tissues were washed in PBS and fixed in 4% paraformaldehyde solution for overnight
and embedded in paraffin. Paraffin sections were stained with hematoxylin and eosin by the
histology core facility at the University of Texas MD Anderson Cancer Center and examined
by a pathologist (MJY). For immunohistochemistry (IHC) staining, standard procedures were
carried out according to the manual (DAKO, #K0673, USA). The stained sections were
automatically processed by ACIS III system (DAKO, USA) and quantified based on 10–15
randomly chosen fields. Quantification of IHC staining was repeated three times by using at
least three different mice per genotype. The following antibodies were used in IHC staining:
P-S6 Ribosomal Protein (#4858, Cell Signaling), P-AKT (#3787, Cell Signaling), P-ERK1/2
(#4376, Cell Signaling), P-P65 (#3037, Cell Signaling), P-STAT3 (#9145, Cell Signaling)
and STAT3 (#9139, Cell Signaling).

2.2.14 Real-time PCR
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Total RNA was isolated using TRIzol RNA isolation reagent (Invitrogen, Grand Island, NY,
USA) and reverse transcribed using SuperScriptIII (Invitrogen). Quantitative PCR was
performed in triplicates using Power SYBR Green PCR Master Mix (Applied Biosystems,
Grand Island, NY, USA).

2.2.15 Statistical analysis
GraphPad Prism software was used for all statistical analyses. The Student’s t-test (two-tailed
t-test) was used to evaluate the difference of two groups of data.
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2.3 Results
2.3.1 MALT1 is required for EGF-induced NF-κB activation
Our previous results revealed that CARMA3, a MALT1-interacting protein, is involved in
EGFR-mediated NF-κB signaling (Jiang et al. 2011). To test whether MALT1 is involved in
EGF-induced NF-κB activation, we knocked down MALT1 expression in A431 cells in
which EGFR is highly expressed and examined NF-κB activation by gel shift assay upon
EGF stimulation. We starved control (shCtl) and MALT1-knockdown (shMALT1) A431 cells
with 0.5% FBS containing DMEM overnight (~16 hours) and stimulated with either EGF
(100 ng/ml) or PMA (50 ng/ml)/Ionomycin (100ng/ml) or TNF𝛼 (10ng/ml) as controls. We
found that the suppression of MALT1 expression significantly impaired EGF- and PMA/
Ionomycin-induced NF-κB activation, respectively, but not tumor necrosis factor-α (TNFα)induced NF-κB activation, indicating that MALT1 is specifically involved in mediating EGFinduced NF-κB activation (Figure 4A). To further confirm the role of MALT1 in EGFinduced NF-κB activation in primary cells, we prepared MALT1-heterozygous (Malt1+/−) and
-deficient (Malt1−/−) primary mouse embryonic fibroblasts (MEFs). Because EGFR
expression in primary MEFs is low, we used PMA (50ng/ml) /Ionomycin (100 ng/ml) to
activate protein kinase C, a downstream component in EGFR signaling, which can induce
NF-κB activation (Stewart and O'Brian 2005, Fan et al. 2009). Consistently, PMA/
Ionomycin-induced NF-κB was completely abolished in MALT1-deficient MEFs (Figure
4b). These data indicates that MALT1 is required for EGFR- and PKC- mediated NF-κB
activation.
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Figure 4. MALT1 is required for EGFR- and PKC-induced NF-𝜅B activation.
(A) A431 cells with a MALT1 knockdown (shMALT1) and control cells (shCtl) were
stimulated with EGF (100ng/ml), PMA and Ionomycin (50ng/ml; 100ng/ml) or TNF (10ng/
ml) for indicated periods. NF-𝜅B activation and Oct-1 (loading control) levels were
determined by the gel shift assay. (B) MEFs from Malt1+/- and Malt1-/- embryos were
isolated. Early-passage (P1) MEFs were stimulated with PMA and Ionomycin (50ng/ml;
100ng/ml) or TNF (10ng/ml) for indicated periods. NF-𝜅B activation and Oct-1 levels were
determined by the gel shift assay.
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2.3.2 MALT1 is specifically required for EGF-induced NF-𝜅B activation and does not
affect other EGFR-activated pathways
To access whether MALT1 is also involved in other EGFR-mediated signaling transduction,
such as PI3K/AKT/mTOR, MAPK/ERK and JNK pathways, we starved control (shCtl) and
MALT1-silenced (shMALT1) A431 cells overnight and stimulated cells with 100ng/ml of
human EGF. We lysed cells at 7.5, 15, 30 and 60 minutes after EGF stimulation and analyzed
the activation of downstream pathways of EGFR. We found MALT1 suppression specifically
abolished EGF-induced p65 nuclear localization (Figure 5A) upon EGF stimulation, but it
had no impact on other pathways downstream of EGFR, as shown by the level of p-S6
Kinase, p-ERK and p-JNK (Figure 5B). These data collectively suggest that MALT1 is
specifically involved in EGFR-mediated NF-𝜅B activation.
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Figure 5. MALT1 is specifically required for EGFR-induced NF-𝜅B activation but not
for other EGFR-downstream pathways.
(A) A431 cells were starved with 0.5% FBS containing DMEM and stimulated with 100ng/
ml of human EGF for indicated time points. Nuclear lysates from control (shCtl) and
MALT1-silenced (shMALT1) cells were analyzed by immunoblotting using indicated
antibodies. (B) Control (shCtl) and MALT1-silenced (shMALT1) A431 cells were stimulated
with EGF (100ng/ml) for indicated periods. Cell lysates were analyzed by immunoblotting
using indicated antibodies. L: Long form of JNK; S: Short form of JNK.
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2.3.3 The protease activity of MALT1 is not required for EGF-induced NF-κB
activation
It has been reported that MALT1 contains protease activity, which is required for
optimal TCR- and BCR-induced NF-𝜅B activity by inhibiting negative regulators in NF-𝜅B
pathway. We therefore sought to determine whether MALT1 protease activity contributes to
EGF-induced NF-κB activation. To this end, we reconstituted MALT1-silenced cells with
either wild-type MALT1 or protease-deficient mutant MALT1 (MALT1C464A) in either
MALT1-silenced A431 cells or MALT1-deficient MEFs (Figure 6A). We found there was a
slight reduction of NF-𝜅B in mutant MALT1 constituted MEFs compared with wild-type
MALT1 reconstituted MEFs upon PMA/Ionomycin stimulation (Figure 6B), indicating
MALT1 protease activity is involved in PKC mediated NF-𝜅B activation. However, both the
wild type and the protease-deficient MALT1 mutant rescued EGF-induced NF-𝜅B in A431
cells (Figure 6C), suggesting the protease activity of MALT1 is largely dispensable for
EGFR-induced NF-𝜅B activation.
As an alternative approach, we examined EGF induced NF-κB activation in the
presence or absence of MALT1 specific inhibitor (z-VRPR-Fmk). While MALT1 inhibitor
completely blocked its protease activity as shown by cleaved BCL10 (Figure 7A), it does not
affect NF-𝜅B activation in response to EGF stimulation in A431 cells (Figure 7B). Taken
together, these results demonstrate that MALT1 mainly functions as a scaffold protein and is
selectively involved in the regulation of EGF-induced NF-𝜅B activation.
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Figure 6. Protease-deficient and wild-type MALT1 reconstitution equally rescued
EGFR- and PMA/Ionomycin-induced NF-𝜅B activation.
(A) MALT1-silenced A431 cells and MALT1-deficient MEFs were reconstituted with wildtype MALT1 (shMALT1WT or Malt1-/-WT) or a protease-deficient C464A mutant
(shMALT1C464A or Malt1-/-C464A). Lysates of these cells were analyzed by immunoblotting
with anti-MALT1 or anti-Flag antibodies. (B) MALT1-deficient cells (Malt1-/-), wild-type
MALT1-reconstituted cells (Malt1-/-WT) and protease-deficient mutant reconstituted cells
(Malt1-/-C464A) were stimulated with PMA and Ionomycin (50ng/ml; 100ng/ml) for indicated
periods, respectively. Nuclear lysates were isolated and subjected to gel shift analysis for
NF-𝜅B activation. (C) A431 cells with a MALT1 knockdown (shMALT1), wild-type
MALT1-reconstituted cells (shMALT1WT) and protease-deficient mutant reconstituted cells
(shMALT1C464A) were stimulated with EGF (100ng/ml) or TNF (10ng/ml) for indicated
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periods. Nuclear lysates were isolated and subjected to gel shift analysis for NF-𝜅B
activation.
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Figure 7. MALT1 protease inhibitor does not affect EGF-induced NF-𝜅B activation.
(A) Jurkat cells were stimulated with PMA and ionomycin (20ng/ml; 100ng/ml) for the
indicated periods with or without 75µM MALT1 inhibitor z-VRPR-Fmk. Whole cell lysates
were analyzed by immunoblotting with the indicated antibodies. (B) A431 cells were
stimulated with EGF (100ng/ml) or TNFα (10ng/ml) for 60 minutes, with or without 75 µM
MALT1 inhibitor z-VRPR-Fmk. Nuclear lysates were isolated and subjected to gel shift
analysis for NF-𝜅B activation.
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2.3.4 MALT1 functions as a scaffold protein to recruit TRAF6 to IKK complex
To further delineate the molecular mechanism by which MALT1 activates NF-𝜅B in response
to EGF stimulation, we examined MALT1-interacting protein upon EGF stimulation. Upon
EGF stimulation, MALT1 was inducibly associated with TRAF6, an E3 ligase that activates
IKK complex (Figure 8A). Consistently, we also observed a notable, but weak association
between MALT1 and IKK at a later time point upon EGF stimulation (Figure 8A), suggesting
that MALT1 bridges TRAF6 to IKK complex in response to EGFR activation. We further
found that the association of MALT1 and TRAF6 was specifically induced by EGF but not
TNF, indicating that MALT1 functions specifically downstream of EGFR (Figure 8B). In
addition, MALT1 silencing abolished the association between IKK𝛾 and TRAF6 upon EGF
stimulation (Figure 8C), suggesting that MALT1 is functionally required for recruiting
TRAF6 to IKK complex upon EGFR activation. To further confirm whether TRAF6 is
functionally required for EGF-induced NF-κB activation, we knocked down TRAF6
expression by shRNA (Figure 8D) and examined NF-κB activation by gel shift assay.
Consistently, TRAF6 inhibition significantly abolished EGF- and PMA/Ionomycin-induced
NF-κB activation, respectively, suggesting that TRAF6 is also required for EGF-induced NFκB activation (Figure 8E). Collectively, these results indicate that MALT1 serves as a
scaffold protein recruiting TRAF6 to activate IKK complex in response to EGFR stimulation.
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Figure 8. MALT1 functions as a scaffold protein to recruit TRAF6 to IKK complex.
(A) MALT1-reconstituted cells were stimulated with EGF (100ng/ml) for indicated time and
MALT1-Flag was immunoprecipitated (IP) by anti-Flag conjugated beads. The IP samples
and lysates were analyzed by immunoblotting using the indicated antibodies. (B) MALT1reconstituted cells were stimulated with EGF (100ng/ml) and TNF𝛼, respectively. MALT1Flag was immunoprecipitated (IP) by anti-Flag conjugated beads. The IP samples and lysates
were analyzed by immunoblotting using the indicated antibodies. (C) Control (shCtl) or
MALT1-silenced (shMALT1) A431 cells were either unstimulated or stimulated with EGF
(100ng/ml) for 15 minutes and IKK𝛾 was immunoprecipitated (IP). The IP samples and
lysates were analyzed by immunoblotting using the indicated antibodies. (D) The lysates of
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A431 cells with control knockdown (shCtl), MALT1 knockdown (shMALT1) and TRAF6
knockdown (shTRAF6) were analyzed by immunoblotting using indicated antibodies. (E)
A431 cells with a TRAF6 knockdown (shTRAF6) and control cells (shCtl) were stimulated
with EGF (100ng/ml), PMA and Ionomycin (50ng/ml; 100ng/ml) or TNF (10ng/ml) for
indicated time points, respectively. NF-𝜅B activation and Oct-1 (loading control) levels were
determined by the gel shift assay.
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2.3.5 MALT1 contributes cell proliferation
Based on the observation that MATL1 is specifically required for EGF-induced NF-κB
activation, we asked whether EGFR-MALT1-NF-𝜅B signaling contributes to EGFRassociated tumor malignancy. To this end, we used both A431 and HCC 827 cell line, which
is a lung cancer cell lines with homozygous constitutive activating EGFR mutation. First, we
examined the role of MALT1 in cell proliferation. We observed a modest suppression of cell
proliferation in MALT1-silenced HCC827 cells compared to controls as determined by MTT
assay (Figure 9A). By using the soft agar colony formation assay to compare anchorageindependent proliferation, we found that MALT1 suppression significantly reduced the size
of colonies formed in the agarose compared with controls in both A431 cells and HCC827
cells (Figure 9B-C), suggesting MALT1 plays a more profound role in 3D proliferation. In
addition, while the size of colonies from control cells increased with the supplementation
with EGF (2ng/ml), MALT1-silenced A431 cells did not increase with the supplementation
with EGF (2ng/ml) (Figure 9 B-C). This result suggests that MALT1-silenced cells do not
respond to EGF stimulation in terms of proliferation. Collectively, these data suggest that
MALT1-dependent NF-𝜅B activity is required for EGFR-dependent cell proliferation in vitro.
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Figure 9. MALT1 contributes to EGFR-associated cell proliferation.
(A) HCC827 cells with MALT1 knockdown (shMALT1) and control cells (shCtl) were
subjected to the MTT assay to determine their proliferation rates at 24, 48, 72 hours. OD,
optical density. (B) A431 (left) and HCC827 (right) cells with a MALT1 knockdown
(shMALT1) and control cells (shCtl) were subjected to soft agar colony formation analysis
with or without EGF (2ng/ml). The sizes of cell colonies were calculated and analyzed. (C)
Representative pictures showing the size of shCtl and shMalt1 colonies of A431 and
HCC827 cells.
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2.3.6 MALT1 contributes to cell migration and metastasis
It has been suggested that NF-𝜅B singling is involved in cell invasiveness by
regulating epithelia-mesenchymal transaction (EMT), a key process in tumor metastasis
(Huber et al. 2004). Therefore, we performed in vitro and in vivo assays in A431 cells, and a
human lung cancer cell line HCC827. First, we found MALT1-silenced cells showed a
dramatical defect in cell migration and motility compared with control cells (shCtl) transwell
migration assay (Figure 10A-B). Consistently, shMALT1 also showed a defect in wound
healing compared with control (Figure 10C). To validate this finding in vivo, We compared
cell metastasis in a lung metastasis model and found that the number of lung metastatic spots
was significantly reduced in MALT1-silenced cells compared to controls (Figure 10D).
To access whether this effect is NF-𝜅B-dependent, we treated cells with IKK
inhibitor, and found that IKK inhibition similarly blocked cell migration in vitro (Figure 11).
In addition, TRAF6-silenced cells showed a consistent defect of cell migration (Figure 11),
which indicates MALT1-TRAF6-IKK signaling controls cell migration. In addition, we
found that treating MALT1 inhibitor does not affect cell migration in either A431 or HCC827
cell lines (Figure 12), suggesting MALT1 protease activity does not contribute to tumor
migration. Taken together, these data suggest that MALT1-mediated NF-𝜅B activity regulates
cell migration in vitro and metastasis in vivo.

62

Figure 10. MALT1 is required for cell migration and metastasis.
(A) A431 and HCC827 cells with a MALT1 knockdown (shMALT1#1 and shMALT1#2) or a
control knockdown (shCtl) were analyzed by transwell migration assays. Cells were fixed
and stained 20 hours after seeding. (B) Cell numbers in five random fields were calculated
and compared. (C) MALT1 silenced A431 cells and controls were analyzed by a woundhealing assay in the presence of EGF (1 ng/ml). The percentage of wound closure were
calculated and analyzed. (D) MALT1 silenced A431 cells and controls were intravenously
injected into SCID mice. Four weeks after injection, mice were sacrificed and the lungs were
washed, fixed and stained with Bouin solution. Metastasis sites were visualized as white
spots (left panel) and quantitated (right panel).
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Figure 11. TRAF6 and IKK complex are required for cell migration.
Transwell migration assays were performed using shCtl A431 cells, shTRAF6 A431 cells and
shCtl A431 cells with IKK inhibitor TPCA (1µM) treatment, respectively. **** p<0.0001.
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Figure 12. MALT1 protease activity is not required for cell migration.
Transwell migration assays were performed using shCtl (A431 and HCC827) cells,
shMALT1 cells and shCtl cells treated with MALT1 inhibitor z-VRPR-Fmk (75µM),
respectively. **** p<0.0001; ns, no significance.
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2.3.7 MALT1 contributes to EGFR-associated lung adenocarcinoma progression in a
mouse model
We sought to establish a physiological model to further investigate whether and how
MALT1-mediated NF-𝜅B activation affects EGFR-driven tumor progression in vivo. Since
EGFR mutation and overexpression have been frequently found in non-small cell lung cancer
(NSCLC), we crossed MALT1-knockout mice to a lung cancer mouse model (tetOEGFRL858R; CCSP-rtTA; Malt1+/- or tetO-EGFRL858R; CCSP-rtTA; Malt1-/-), in which mutant
EGFR-driven lung cancer will be developed in the presence or absence of MALT1
expression (Figure 13A). After we successfully got EGFRL858R/CCSP-rtTA/Malt1+/-- and
EGFRL858R/CCSP-rtTA/Malt1-/--triple transgenic mice, we found both Malt1 heterozygous
and knockout mice express human EGFR mRNA in a similar level, indicating that MALT1
does not affect the expression and induction of mutant EGFR transgene (Figure 13B). To
access lung tumor burden, we compared the ratio of lung weight to body weight. We found
that Malt1 knockout mice showed significant lower ratio of lung to body weight compared
with heterozygous controls (0.0350 ± 0.001570, n=8 vs. 0.02771 ± 0.001672, n=7 p=0.0073)
(Figure 13C), suggesting a reduced lung tumor burden in Malt1 knockout mice. We reviewed
the pathological slides of lung tissue and found that mice with homozygous Malt1 knockout
showed a reduced level of cellularity and the frequency of atypical cells with irregular nuclei
in lungs in comparison with Malt1 heterozygous controls, suggesting a less malignant
phenotype in Malt1 homozygous knockout mice (Figure 13D). In addition, Malt1
heterozygous lungs also had less alveolar space and more frequent focal glandular neoplasms
compared with Malt1 knockout littermates (Figure 13D). Collectively, these data suggests
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that Malt1 homozygous knockout mice had a reduced lung cancer burden and malignancy
compared with its heterozygous controls.
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Figure 13. MALT1 contributes to EGFR-associated lung adenocarcinoma progression
in a mouse model.
(A) Graphic presentation of the generation of tetO-EGFRL858R ; CCSP-rtTA; MALT1-/- tripletransgenic mice. (B) Total RNA were extracted from the lungs of tetO-EGFRL858R; CCSPrtTA; Malt1+/- mice (Het), tetO-EGFRL858R; CCSP-rtTA; Malt1-/- mice (KO), and HeLa cells,
respectively. Reverse transcription PCR was performed using primers to amplify human
EGFR and mouse LCa3, respectively. (C) The ratio of lung to body weight was compared
between tetO-EGFRL858R; CCSP-rtTA; MALT1+/- (Het) (n=8) and tetO-EGFRL858R ; CCSPrtTA; MALT1-/- (KO) mice (n=7). **, p<0.01. (D) H&E staining of the normal lung (NL),
lung from tetO-EGFRL858R ; CCSP-rTTA; MALT1+/- mice (Het) and lung from tetOEGFRL858R ; CCSP-rTTA; MALT1-/- mice (KO).
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2.3.8 MALT1 is not required for K-ras-induced lung adenocarcinoma progression
Since MALT1 is specifically involved in EGFR but not K-ras induced NF-𝜅B
activation, we would like to examine whether MALT1 is specifically required for EGFRinduced NF-𝜅B activation. To this end, we also generated another mouse model in which
lung tumor is driven by mutant K-ras expression with or without MALT1 expression (LSLK-rasG12D; CCSP-Cre; MALT1+/- or LSL-K-rasG12D; CCSP-Cre; MALT1-/-) (Figure 14A).
However, we observed similar tumor burdens (0.01573 ± 0.001575, n=5 vs. 0.01548 ±
0.001560, n=5) between control mice (LSL-K-rasG12D; CCSP-Cre; MALT1+/-) and MALT1
deficient mice (LSL-K-rasG12D; CCSP-Cre; MALT1-/-) (Figure 14B). The number of visible
tumors on the surface of lungs were also similar between control mice and MALT1 deficient
mice (Figure 14C). In terms of histology, both control mice and MALT1 deficient mice
develops similar size and pathology of lung adenocarcinoma (Figure 14D). Therefore, these
data indicate that MALT1 contributes to EGFR-induced but not K-ras-induced lung tumor
progression in vivo.
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Figure 14. MALT1 is dispensable for K-ras-induced lung adenocarcinoma progression.
(A) Graphic presentation of the generation of LSL-K-rasG12D; CCSP-Cre; MALT1-/- tripletransgenic mice. (B) The ratio of lung to body weight was compared between LSL-K-rasG12D;
CCSP-Cre; MALT1+/- (Het) (n=5) and LSL-K-rasG12D; CCSP-Cre; MALT1-/- (KO) mice
(n=5). ns, no statistically significance. (C) The number of tumors on the lung in LSL-KrasG12D; CCSP-Cre; MALT1+/- (Het) (n=3) and LSL-K-rasG12D; CCSP-Cre; MALT1-/- (KO)
mice (n=3). ns, no statistically significance. (D) H&E staining of the lung from LSL-KrasG12D ; CCSP-Cre; MALT1+/- mice (Het) and lung from LSL-K-rasG12D ; CCSP-Cre;
MALT1-/- mice (KO). Arrow shows tumor cells.
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2.3.9 MALT1 contributes to NF-𝜅B and STAT3 activation in vivo
To further dissect how MALT1 deficiency inhibits EGFR-dependent tumor growth,
we examined the activation of downstream pathways of EGFR. Consistent with our in vitro
data, we found a lower NF-𝜅B activity in Malt1-knockout tumor bearing lungs compared
with controls as showed by a reduced level of phosphorylated p65, while the level of
phosphorylated-S6 ribosomal protein, phosphorylated AKT and phosphorylated ERK
remained similar between Malt1 heterozygous and knockout mice (Figure 15). These results
were consistent with our observation in vitro and suggest that MALT1 affects NF-𝜅B
activation in vivo.
It has been shown that STAT3 is also one of the downstream effectors of EGFR and is
activated in EGFR-associated lung tumor in both mouse models and human samples (Gao et
al. 2007). To our surprise, we found a significant defect of phosphorylated STAT3 level in
Malt1-knockout mice compared with its heterozygous control, while the level of total STAT3
is comparable between Malt1 heterozygous and knockout mice (Figure 15). Thus, our data
also suggest that MALT1 contributes to the EGFR-dependent activation of STAT3 in vivo.
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Figure 15. MALT1 controls NF-𝜅B and STAT3 activation in EGFR-driven lung cancer
model.
(A) Representative IHC staining of lung sections from tetO-EGFRL858R; CCSP-rtTA;
MALT1+/- and tetO-EGFRL858R; CCSP-rtTA; MALT1-/- mice by using indicated antibodies.
(B) The intensity × percentage of positive signals in (A) were compared for each staining.
10-15 random fields were chosen for each genotype, and were repeated three times using
different mice (n=3) for each genotype.
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2.3.10 MALT1 controls NF-𝜅B dependent IL-6 production in response to EGFR
It has been suggested that NF-𝜅B regulates IL-6 production. We found both IL-6
neutralization and IKK inhibition significantly reduced p-STAT3 level in HCC827 cells,
suggesting that both NF-𝜅B and IL-6 are required for p-STAT3 activation in HCC827 cells
(Figure 16). In addition, MALT1-silenced HCC827 cells showed a lower level of p-STAT3
compared with control cells. This result is consistent with a lower p-STAT3 level in the lung
tumor from MALT1 deficient mice compared with the control mice in vivo. To further
determine whether MALT1 controls IL-6 production upon EGFR activation, we took A431
cells and examined IL-6 production upon EGF stimulation. We found MALT1-silenced cells
produced significant less IL-6 compared to controls, while cells treated with MALT1
inhibitor produced similar amount IL-6 production as control (Figure 17A). Consistently,
MALT1-silenced HCC827, but not cells treated with MALT1 inhibitor, showed a similar
defect in IL-6 production (Figure 17B). In our mouse model, we found that IL-6 mRNA level
is much lower in the tumor bearing lungs of Malt1 knockout mice compared to its
heterozygous controls (Figure 17C). Taken together, these data indicate that MALT1 controls
EGFR-driven IL-6 production in vitro and in vivo. In summary, our data suggests that
MALT1 contributes EGFR-associated lung cancer progression by coordinately controlling
both NF-𝜅B and STAT3 activation through IL-6-mediated crosstalk between these two
pathways (Figure 18).
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Figure 16. IL-6 and IKK complex are required for STAT3 activation in vitro.
Control (shCtl) and MALT1-silenced (shMalt1) HCC827 cells were treated with IL-6
neutralizing antibodies and IKK inhibitor TPCA (1µM) for 12 hours, respectively. Lysates of
these cells were analyzed by immunoblotting with indicated antibodies. Band intensity was
quantified by using Image J.
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Figure 17. MALT1 is required for EGFR-induced IL-6 production.
(A) Control A431 cells (shCtl), MALT1 knockdown cells (shMALT1), and control cells
treated with MALT1 inhibitor z-VRPR-Fmk (75𝜇M) were stimulated with EGF (100ng/ml),
respectively. Total RNA was extracted for quantitative PCR analysis. The ratio of mRNA of
human IL-6 to human HPRT1 were calculated and compared in the graph. *, p<0.05. (B)
Total RNA was extracted from control (shCtl) HCC827 cells, MALT1 knockdown cells
(shMALT1), and control cells treated with MALT1 inhibitor z-VRPR-Fmk (75µM),
respectively. The ratio of mRNA of human IL-6 to human HPRT1 were calculated and
compared in the graph. *, p<0.05. (C) Total RNA was extracted from the lung of tetOEGFRL858R ; CCSP-rtTA; MALT1+/- and tetO-EGFRL858R ; CCSP-rtTA; MALT1-/- mice. The
ratio of IL-6 to GAPDH was presented in the graph. *, p<0.05.
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Figure 18. The working model summarizing the finding in this study.
MALT1 is required for EGFR-induced NF-𝜅B activation by recruiting E3 ligase TRAF6 to
induce the activation of the IKK complex. The EGFR-activated NF-𝜅B is responsible to
transcribe IL-6, which in turns to activate STAT3 pathway. Together, NF-𝜅B and STAT3
signaling coordinately promote EGFR-associated lung cancer progression.
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2.4 Discussion
2.4.1 MALT1 only functions as a scaffold protein in EGFR-mediated NF-𝜅B pathway
NF-κB is one transcription factor that has been shown directly activated by EGFR.
Although previously it has been shown that EGFR activates NF-𝜅B in a CARMA3- and
BCL10-dependent manner, the exact molecular mechanism by which EGFR activates NF-𝜅B
is still not clear. In this study, we have provided biochemical and genetic evidence suggesting
that EGFR-induced NF-𝜅B is mediated by MALT1. We found that MALT1 functions
downstream of BCL10 and recruits E3 ligase TRAF6 to IKK complex upon EGFR
stimulation. In lymphocytes, the activation of NF-𝜅B requires two parallel signals to induce
IKK ubiquitination and phosphorylation in response to TCR and BCR stimulation
(Shambharkar et al. 2007). A previous report suggests that EGFR activation induce IKK
phosphorylation through PKC (Yang et al. 2012). Since we found MALT1 deficiency does
not alter the level of phosphorylated IKK in response to EGF stimulation, we propose that
MALT1-TRAF6 complex is responsible for IKK ubiquitination in response to EGF
stimulation. This activation mechanism is similar to TCR- and BCR-induced NF-κB.
However, unlike TCR- and BCR-induced NF-𝜅B, the protease activity of MALT1 is not
required for EGFR-induced NF-𝜅B activation, although we found there was a slight
reduction of PMA/Ionomycin induced NF-κB in MEFs. This result is in part due to lack of
MALT1’s substrates in non-hematoploitic cells, such as A20 and RelB. It may also due to
EGFR does not activate NF-𝜅B as strong as CD3/CD28 or PMA and Ionomycin does.
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However, even the cells express CYLD, which is cleaved by MALT1 in response to TCR
stimulation (Staal et al. 2011), we cannot detect proteolysis events upon EGF stimulation.
Therefore, our results suggest a differential requirement of MALT1 protease activity
depending different types of stimuli.

2.4.2 MALT1 in EGFR-associated tumor malignancy
EGFR is playing an oncogenic role in many types of human cancer. While it has been
well established that EGFR downstream effector pathways such as AKT and MAPK are
playing pivotal roles in cancer initiation and progression, less is known about how other
signaling such as NF-𝜅B contributes to EGFR-associated tumor progression. Here we show
MALT1 contributes to several important oncogenic phenotypes in EGFR-associated tumors.
Our study found that MALT1 plays an essential role in tumor migration and invasion in vitro,
as well as in a lung metastasis model in vivo. We propose such defect is through NF-𝜅Bdependent gene expression based on the data that MALT1 deficiency specifically blocks
NF-𝜅B activation but not other signaling pathways downstream of EGFR. In line with this
notion, inhibition of IKK kinase activity and TRAF6-silencing phenocopy MALT1-silencing
in terms of cell migration, suggesting that MALT1 controls cell migration through NF-𝜅B
pathway. Indeed, our microarray data revealed that the expression of several matrix
metalloproteinases (MMPs) is significantly down regulated in response to EGF stimulation in
CARMA3-silenced cells (data not shown). This is consistent with the notion that NF-𝜅B
regulates the expression of many genes involved in migration and invasion (Huber et al.
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2004). However, MALT1 may also contribute to migration and invasion in an NF-𝜅Bindependent manner. For example, a recent study showed that BCL10 regulates actin
dynamics and polymerization (Rebeaud et al. 2008). Therefore, it is possible that MALT1
also affects tumor cell migration and invasion by regulating these processes.
Although study from our group and others suggests that NF-𝜅B is an important
transcription factor for EGFR-associated malignancy (Jiang et al. 2011), this notion has not
been tested in physiological tumor models. In this study, we used an EGFR-driven lung
cancer mouse model to test how MALT1 is involved in the progression of EGFR-induced
lung tumor progression. Our model shows that MALT1 dependent NF-𝜅B contributes to the
progression of EGFR-induced adenocarcinoma, but is not required for the tumor onset. This
result highly correlates with our in vitro data that MALT1 inhibition suppresses tumor growth
but does not completely suppress tumor cells. Interestingly, although NF-𝜅B activity has
been shown to be important to K-ras dependent lung cancer progression (Meylan et al. 2009),
MALT1 is dispensable for both onset and progression of K-ras-induced lung cancer. This
finding is consistent with the hypothesis that MALT1 is specifically involved in EGFRinduced NF-𝜅B activation but not K-ras-mediated NF-𝜅B, which is likely mediated by TBK1
(Barbie et al. 2009). Therefore, our result has provided the genetic evidence supporting a
rationale of targeting MALT1 or other components in NF-𝜅B signaling in EGFR-associated
lung cancer.
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2.4.3 The role of MALT1 in STAT3 pathway in lung cancer
Another interesting finding in this study is that MALT1 deficiency abolishes the
activation STAT3 in vivo. Previous studies suggest constitutively activated STAT3 is found in
50% of human NSCLC samples (Gao et al. 2007). In addition, a blockage of STAT3 induces
growth arrest of tumor, suggesting the functional importance of STAT3 in EGFR-associated
lung cancer (Gao et al. 2007). However, how STAT3 is aberrantly activated in NSCLC is not
clear. Here, we provide genetic evidence suggesting that STAT3 activation in NSCLC is
likely controlled by MALT1-dependent NF-𝜅B activation. This result suggests that NF-𝜅B
not only controls cell proliferation and survival by itself, but also indirectly activate STAT3.
Therefore, a blockage of the crosstalk between NF-𝜅B and STAT3 can be used as a potential
therapeutic strategy for the treatment of EGFR-associated lung cancer. In the current study,
we showed that IL-6 is one of the effectors that bridging NF-𝜅B to STAT3 in response to
EGFR activation. This result supports an idea to block IL-6 in EGFR-dependent lung cancer
to interrupt the crosstalk between NF-𝜅B and STAT3. In fact, elevated IL-6 level has been
connected to the survival of patients with advanced NSCLC (Songur et al. 2004). As antiIL-6 and anti-IL-6 receptor antibodies are currently tested in several clinical studies including
some types of cancers (Guo et al. 2012), targeting IL-6 in EGFR-dependent NSCLC is worth
to be tested in preclinical models in the future.
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3.1 Introduction
3.1.1 Overview of HER2 and breast cancer
The human epidermal growth factor receptor 2 (Her2)/Neu protein is one of the
members of the epidermal growth factor receptor (EGFR) family. Amplification and
overexpression of HER2/Neu have been found in approximately 20-30% of breast cancers
(Mitri et al. 2012). In addition, HER2 amplification and overexpression are associated with
poor prognosis in patients with breast cancer. Although targeted therapy against HER2, such
as Trastuzumab, has been shown to work well against HER2-positive breast cancer, most
patients were found to develop acquired resistance within 1 year of treatment (Rexer and
Arteaga 2013). Therefore, seeking new therapeutic targets downstream of HER2 signaling
may provide alternative therapies for HER2-positive breast cancers.

3.1.2 The role of NF-𝜅B signaling in HER2+ breast cancer
NF-𝜅B is part of a family of transcription factors that regulate the expression of a
wide variety of genes, including those involved in cell survival and inflammation (Hayden
and Ghosh 2012). It has been proposed that NF-𝜅B plays a crucial role in the progression of
many types of tumors, including HER2-positive breast cancer (Bailey et al. 2014). For
example, it has been shown that NF-𝜅B is crucial for cell proliferation and invasion in
HER2-positive breast cancer cells (Merkhofer et al. 2010). In addition, the activation of NF𝜅B has been functionally linked to drug resistance in both HER2-positive and negative breast
cancer cells (Bailey et al. 2014, Oida et al. 2014). Although it has been suggested that NF-𝜅B
82

regulates many aspects of HER2-positive breast cancer progression, little is known about the
mechanistic relationship between HER2 activation and NF-𝜅B activation.
NF-𝜅B transcription factors include five subunits, RelA, RelB, c-REL, p105/p50 and
p100/p52. Canonical NF-B activation requires an upstream signal that activates the IB kinase
(IKK) complex, which phosphorylates I𝜅B and triggers its degradation via the ubiquitination/
proteasome pathway. The degradation of I𝜅B releases NF-B subunits to the nucleus and
initiates transcription. It has been previously suggested that HER2-induced NF-𝜅B activation
is mediated by AKT activation (Pianetti et al. 2001). However, a later study showed that AKT
is not required for the HER2-induced NF-𝜅B activation (Merkhofer et al. 2010). The same
study further suggested that HER2 activates NF-𝜅B through a canonical pathway that
depends on IKK𝛾, a component of IKK complex (Merkhofer et al. 2010). However, the
molecular link between HER2 and the IKK complex still remains to be determined.

3.1.3 Critical observations and hypothesis
The caspase recruitment domain (CARD) and membrane-associated guanylate
kinase-like domain protein (CARMA) family of proteins includes CARMA1, CARMA2 and
CARMA3 (Blonska and Lin 2011). CARMA1 is expressed predominantly in the lymphoid
cells and is required for T cell receptor (TCR)- and B cell receptor (BCR)-induced NF-𝜅B
activation (Gaide et al. 2002, Wang et al. 2002). The activation of CARMA1 triggers the
association of CARMA1 with B-cell lymphoma 10 (BCL10) and mucosa associated
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lymphoid tissue lymphoma translocation protein 1 (MALT1), and forms CARMA1-BCL10MALT1 (CBM) complex. The CBM complex recruits E3 ligases such as TRAF6 to activate
IKK complex via ubiquitination in response to T cell receptor stimulation (Sun et al. 2004).
Similarly, CARMA3 is mainly expressed in the non-hematopoietic cells and is required for
protein kinase C (PKC)-induced NF-𝜅B activation, in which CARMA3 forms the CBM
complex through a similar mechanism as that of CARMA1 (Jiang and Lin 2012). In our
previous studies, we found that the CBM complex is required for G protein coupled receptor
(GPCR)- and EGFR-induced NF-𝜅B activation (Grabiner et al. 2007, Jiang et al. 2011, Pan et
al. 2015). Therefore, we hypothesized that the CBM complex mediates HER2-induced NF𝜅B activation and contributes to HER2-associated tumor malignancy. In the current study,
we used biochemical and genetic approaches to investigate the role of the CBM complex in
HER2-mediated NF-𝜅B activation and HER2-positive breast cancer.
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3.2 Materials and Methods
3.2.1 Antibodies and reagents
Antibodies against phospho-EGFR (sc-12351), EGFR (sc-03), BCL10 (sc-5611), ERK
(sc-154), Neu (sc-284), and Actin (sc-8432), were purchased from Santa Cruz Biotechnology
(Dallas, TX). Antibodies against p-AKT (Ser473; 9271S), p-AKT (Thr308) (9275), AKT
(4685), p-ERK1/2 (9101), p-IkBa (9246) and p-HER2 (2241) were purchased from Cell
Signaling Technology (Danvers, MA). Monoclonal antibodies against MALT1 were
generated by Genentech (San Francisco, CA). Human heregulin-b-1 (Cat. #AF-100-03) was
purchased from Pepro Tech (Rocky Hill, NJ). Recombinant human EGF was purchased from
Sigma-Aldrich (St. Louis, MO). Phorbol 12 myristate 13 acetate (PMA; 16561-29-8) and
ionomycin (56092-82-1) were purchased from Fisher BioReagents (Pittsburgh, PA). TNF𝛼
was purchased from Thermo Fisher Scientific (Rockford, IL). Akt1/2 kinase inhibitor
(A6730) was purchased from Sigma-Aldrich (MO, USA).

3.2.2 Cells
SKBR3 cells were grown in McCoy’s medium containing 10% fetal bovine serum at
37ºC with 5% CO2. Mouse embryonic fibroblasts were cultured in Dulbecco’s modified
Eagle medium containing 10% fetal bovine serum at 37ºC with 8% CO2.

3.2.3 Immunoblotting and gel shift assay
These experiments were performed as described (Pan et al. 2015). For immunoblotting
assay, one million of cells were lysed in 100𝜇l of lysis buffer (150 mM NaCl, 50 mM HEPES
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at pH 7.4, 1 mM EDTA, 1% NP-40, protease inhibitors) for 10 minutes. The cell lysates will
be purified by spinning 13,000 r.p.m. for 10 minutes and resulting supernatants will be saved
for western blot analysis. 10-12𝜇l of the resulting supernatant were loaded to 10% of SDSPAGE and probed with antibodies. For the electrophoretic mobility shift assay, two million
cells were starved overnight in DMEM containing 0.5% serum and stimulated with reagents,
and nuclear extracts were isolated. Nuclear extracts (5 µg) were incubated with 1 × 105 c.p.m.
of 32P-labeled probes at room temperature for 15 min. The samples were separated on a
native Tris-borate-EDTA polyacrylamide gel and analyzed by autoradiography.

3.2.4 cDNA preparation and Quantitative PCR
Total RNA was extracted using TRIzol Reagent (Life Technologies, Grand Island, NY)
according to manufactory protocol. cDNA was synthesized by using iScript cDNA synthesis
Kit (Bio-Rad, Hercules, CA). Quantitative polymerase chain reaction (PCR) was performed
by using the Fast SYBR green master Kit (Life Technologies, Grand Island, NY) according
to the protocol. Primers for quantitative PCR were described as follows. CARD10-F: 5’
CCCGCACCCCCTAAGAGA 3’; CARD10-R: 5’ TGTCAGAGGATGAGGACGAAGA3’;
MMP1-F: 5’GAGCTCAACTTCCGGGTAGA3’; MMP1-R: 5’
CCCAAAAGCGTGTGACAGTA3’; MMP3-F: 5’ CAAAGCTTCAGTGTTGGCTG3’;
MMP3-R: 5’ GGCCAGGGATTAATGGAGAT3’; MMP7-F: 5’
GGCCAAAGAATTTTTGCATC3’; MMP7-R: 5’GAGCTACAGTGGGAACAGGC3’;
MMP13-F: 5’ ACTGAGAGGCTCCGAGAAATG3’; MMP13-R: 5’
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GAACCCCGCATCTTGGCTT3’; MMP14-F: 5’ GGCTACAGCAATATGGCTACC3’;
MMP14-R: 5’ GATGGCCGCTGAGAGTGAC3’.

3.2.5 Cell migration and invasion assay
We added 1x105 SKBR3 cells to a cell culture insert (353097, Franklin Lakes, NY) and
the lower chambers were placed with 0.7 ml of serum-free medium containing 50 ng/ml
heregulin (HRG) or complete medium containing 10% fetal bovine serum (FBS). After 16
hours of incubation, migrated cells were fixed, stained and quantified. The cell invasion
assay was performed in a similar manner to the migration assay with matrigel on the lower
chamber. After 48 hours of incubation, migrated cells were fixed, stained and quantified.

3.2.6 MTT Assay
SKBR3 cells were seeded in wells of a 96-well plate in 100𝜇l of complete or serum-free
(0.5% FBS) of MyCoy’s media. At the indicated time, 10𝜇l of MTT reagent (5mg/ml) was
added to the cells. After 3 hours of incubation, the media containing MTT was removed and
metabolized MTT will be dissolved in 100𝜇l of DMSO. The absorbance was measured at
570nm and was recorded accordingly.

3.2.7 Colony formation assay
These experiment were performed as described previously (Pan et al. 2015). For colony
formation assay, SKBR3 cells were mixed with agarose to a final concentration of 0.6% in

87

complete medium, with or without HRG (1 ng/ml). Three weeks after culturing, the numbers
and sizes of colonies were determined by inverted microscopy. Nine to ten fields were
randomly selected and the size of each colony visualized was determined.

3.2.8 Anoikis assay
We mixed 1x106 cells with complete medium containing 1% methylcellulose in the
presence or absence of 10ng/ml HRG and seeded this mixture in 6-well plates coated with 2
ml of poly 2-hydroxyethyl methacrylate (10 g/L in 100% ethanol; 25249-16-5, SigmaAldrich). The cells were incubated at 37ºC for 72 hours and stained with Annexin V and
propidium iodide according to manufactory protocol (556547, BD Biosciences, San Jose, CA
). The stained cells were analyzed using a flow cytometer (Becton Dickinson FACS Canto
II).

3.2.9 Mouse xenograft tumor model
Six-week-old female SCID mice were used for this experiment. We suspended 1x106
cells in a 1:3 mixture of appropriate medium versus matrigel and injected subcutaneously
into the fat pad of SCID mice. Six weeks after inoculation, mice were euthanized and the
tumor size was measured. All animal experiments and procedures were conduced under the
protocol and were approved by the Institutional Animal Care and Use Committee (IACUC)
at the The University of Texas MD Anderson Cancer Center.
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3.2.10 Mouse lung metastatic tumor model
Six-week-old female SCID mice were used for the lung metastatic animal model. We
suspended 1x107 cells in serum free medium and injected the cells into tail vein. Six weeks
after injection, the animals were euthanized and the lungs were washed, fixed and stained in
Bouin's solution. Metastatic lesions were photographed and counted.

3.2.11 Mammary tumor mouse model
Malt1 knockout mice (Ruefli-Brasse et al. 2003) were backcrossed to 6 generations
with the FVB/N background and then crossed with MMTV-Neu-NDL mice (Siegel et al.
1999), which are maintained with a pure FVB/N background. After 12 weeks, female mice
were palpated weekly to determine whether the tumors have developed. Mice were
euthanized when the tumor size reached 100mm in diameter. Statistical analysis of mouse
survival was performed using survival curve parameters (Log-rank test) in Prism GraphPad 6
(La Jolla, CA).

3.2.12 Histology and immunohistochemical staining
Mammary tumors isolated from MMTV-Neu mice were washed in phosphate-buffered
saline and fixed in 4% paraformaldehyde solution for overnight and embedded in paraffin.
The paraffin sections were stained in hematoxylin and eosin by the histology core facility at
MD Anderson. For immunohistochemical (IHC) staining, standard procedures were carried
out according to the manual (DAKO, #K0673, Carpinteria, CA).
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3.2.13 Statistical analysis
All groups were compared using the Student’s t test (2-tailed unpaired t test) in Prism
Graphpad 6 unless otherwise indicated. p<0.05 was considered statistically significant.
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3.3 Results
3.3.1 PKC but not AKT activity is required for HER2-induced NF-𝜅B activation
The role of PI3K-AKT in HER2-induced NF-B activation remains controversial
(Pianetti et al. 2001). To determine whether PI3K-AKT signaling is required for HER2induced NF-𝜅B activation in breast cancer cell lines, we tested the effect of an AKT inhibitor
on NF-𝜅B activation in response to stimulation of HRG in SKBR3 cells, in which HER2 is
highly expressed. To ensure the specificity of HRG to HER2 activation, we first confirmed
that HRG only activates only HER2 and not EGFR in SKBR3 cells (Figure 19). We found
that although the AKT inhibitor specifically and efficiently blocked the activation of AKT in
response to HRG stimulation (Figure 20A), the activation of NF-kB was intact in the
presence of the AKT inhibitor compared with controls, as determined by the gel shift assay
(Figure 20B). This result suggests that AKT activity is dispensable for HER2-induced NF-B
activation. In contrast, we found that HER2-induced NF-B activation was completely
blocked in SKBR3 cells treated with PKC inhibitor (GF209103X) (Figure 21A). The PKC
inhibitor specifically affected PMA- and ionomycin- but not TNF-induced NF-B (Figure
21B). In addition, the PKC inhibitor had no effect on HER2 activation or its other
downstream targets such as ERK activation (Figure 21C). Taken together, these data indicate
that HER2-induced NF-𝜅B activation requires PKC rather than AKT activity.
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Figure 19. Heregulin specifically activates HER2 receptor.
SKBR3 cells were stimulated with EGF (100ng/ml) or HRG (50ng/ml) for 7.5, 15 or 30
minutes. Whole cell lysates were subjected to immunoblotting with the indicated antibodies.
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Figure 20. HER2-induced NF-𝜅B activation does not require AKT activity.
(A) SKBR3 cells were treated with AKT1/2 kinase inhibitor (20𝜇M) or vehicle control and
stimulated with heregulin (HRG; 50ng/ml) for 30 or 60 minutes. Whole cell lysates were
subjected to immunoblotting with indicated antibodies. (B) Nuclear extracts from the
experiment shown in panel A were isolated and subjected to the gel shift assay using probes
binding to NF-B or Oct-1 (loading control).
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Figure 21. HER2-induced NF-𝜅B activation requires PKC activity.
(A) SKBR3 cells were treated with a PKC inhibitor (GF209103X; 1uM) or vehicle control
and were stimulated with HRG (50ng/ml),phorbol 12 myristate 13 acetate (50ng/ml) and
ionomycin (100ng/ml), or TNF (10ng/ml) for 1 hour. Whole cell lysates were subjected to
immunoblotting with the indicated antibodies. (B) Nuclear extracts from same experiment
shown in panel C were isolated and subjected to the gel shift assay using probes binding to
NF-𝜅B or Oct-1 (loading control). Experiments have been independently repeated 2-3 times.
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3.3.2 The CBM complex is required for HER2-induced NF-𝜅B activation
It has been shown that the CBM complex is positioned immediately downstream of
PKC in response to several types of stimuli, such as T cell and B cell receptor and GPCR
stimulation (Blonska and Lin 2009). Therefore, we sought to determine whether the CBM
complex also links PKC to NF-𝜅B activation in response to HER2 stimulation. We silenced
the expression of CARMA3, BCL10 and MALT1, respectively, in SKBR3 cells by infecting
cells with shRNA (Figure 22) and examined NF-𝜅B activation after HRG stimulation using
the gel shift assay. We found that HER2-induced NF-𝜅B activation was significantly reduced
in CARMA3, BCL10 and MALT1-silenced SKBR cells, respectively (Figure 23A-B).
Consistently, HER2-induced NF-𝜅B activation was also abolished in CARMA3 deficient
(Card10-/-) mouse embryonic fibroblasts (MEFs) compared with wild-type (Card10+/+)
controls (Figure 23C). In addition, CARMA3 or BCL10 silencing specifically inhibited the
activation of NF-𝜅B, but not the AKT pathway, as determined by the level of both
phosphorylated AKT (Thr 308) and phosphorylated AKT (Ser 473) after HRG stimulation
(Figure 24). Taken together, these results indicate that the CBM complex is specifically
required for HER2-induced NF-𝜅B activation.
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Figure 22. Knockdown efficiency of CARMA3, BCL10 and MALT1.
(A) Total RNA from SKBR3 cells with control knockdown (shCtl) or CARMA3 knockdown
by 1 of 2 different shRNA (shCARMA3-1 and shCARMA3-2) were extracted for
quantitative PCR analysis to determine the relative expression level of CARMA3 to
GAPDH. (B-C) Whole cell lysates from SKBR3 cells with control knockdown (shCtl),
BCL10 knockdown, or MALT1 knockdown were subjected to immunoblotting with the
indicated antibodies.
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Figure 23. The CARMA3-BCL10-MALT1 complex is required for HER2-induced NF𝜅B activation.
(A) SKBR3 cells with control knockdown (shCtl), BCL10 knockdown (shBCL10), or
CARMA3 knockdown by 1 of 2 different shRNAs (shCARMA3-1 and shCARMA3-2) were
stimulated with heregulin (HRG; 50ng/ml) or TNF (10ng/ml) for 1 hour. Nuclear extracts
were isolated and subjected to the gel shift assay by using probes binding to NF-𝜅B or Oct-1
(loading control). (B) SKBR3 cells with control knockdown (shCtl), or MALT1 knockdown
(shMALT1) were stimulated with HRG (50ng/ml) or TNF (10ng/ml) for 1 hour. Nuclear
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extracts were isolated and subjected to the gel shift assay by using probes binding to NF-𝜅B
or Oct-1 (loading control). (C) Wild-type (Card10+/+) and CARMA3-deficient (Card10-/-)
mouse embryonic fibroblasts were stimulated with HRG (50ng/ml) for 30 and 60 minutes or
with TNF (10ng/ml) for 30 minutes. Nuclear extracts were isolated and subjected to the gel
shift assay by using probes binding to NF-𝜅B or Oct-1 (loading control). Experiments have
been independently repeated 2-3 times.
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Figure 24. CARMA3 and BCL10 do not affect HER2-induced AKT activation.
SKBR3 cells with control knockdown (shCtl), BCL10 knockdown (shBCL10), or CARMA3
knockdown (shCARMA3-2) were stimulated with HRG (50ng/ml) for 7.5, 15 or 30 minutes.
Whole cell lysates were subjected to immunoblotting with the indicated antibodies.
Experiments have been independently repeated 2-3 times.
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3.3.3 The CBM complex contributes to cell proliferation and avoidance of apoptosis
Because NF-𝜅B plays a critical role in cell survival, we examined the contribution of
CARMA3 and BCL10 to cell proliferation and survival in SKBR3 cells. We found that cells
with silenced CARMA3 or BCL10 proliferated at a significantly slower rate than control
cells (Figure 25A). The difference was more dramatic in the presence of HRG, suggesting
that CARMA3 and BCL10 are required for HRG-stimulated cell proliferation (Figure 25B).
We also found that cells with silenced CARMA3, BCL10 or MALT1 become more sensitive
to detachment induced cell apoptosis, a phenomenon called “anoikis,” compared with control
cells (Figure 26). Taken together, these data suggest that CARMA3 and BCL10 are required
for HRG-stimulated cell proliferation and cell survival in vitro.
To examine the role of the CBM complex in terms of tumor growth, we used the
colony formation assay to determine whether the CBM complex contributes to tumor
formation in vitro. We found that SKBR3 cells with silenced CARMA3 or BCL10 formed
fewer colonies on the soft agar than did control cells (Figure 27A-B). Similarly, cells with
silenced MALT1 also formed much smaller colonies than did control cells (Figure 27C).
These results suggest that the CBM complex is required for tumor formation in vitro.
To further investigate the role of CARMA3 in tumor formation in vivo, we performed
xenograft experiment by injecting CARMA3-silenced or control SKBR3 cells into SCID
mice. Consistent with the results of the colony formation assays, we found that CARMA3silenced SKBR3 cells formed significantly smaller tumors than control cells (Figure 28),
suggesting that CARMA3 also contributes to the tumor growth in vivo. Collectively, these
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results indicate that the CBM complex contributes to the proliferation and survival of SKBR3
breast cancer cells in vitro and in vivo.
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Figure 25. CARMA3 and BCL10 are required for SKBR3 cell proliferation.
(A) SKBR3 cells with control knockdown (shCtl), BCL10 knockdown (shBCL10), or
CARMA3 knockdown by 1 of 2 different shRNAs (shCARMA3-1 and shCARMA3-2) were
subjected to the colony formation assay in the presence or absence of 10 ng/mL heregulin for
2 weeks. Five random fields were photographed; one was presented here. (B) Quantification
of colonies in panel A in the presence or absence of HRG. Experiments have been
independently repeated 2-3 times.
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Figure 26. CARMA3 and BCL10 are required for detachment induced apoptosis in
SKBR3 cell line.
SKBR3 cells with control knockdown (shCtl), BCL10 knockdown (shBCL10), or CARMA3
knockdown (shCARMA3) were mixed with complete medium containing 1%
methylcellulose in the presence or absence of 10ng/ml heregulin. After 48 hours, apoptotic
cells were examined by staining with Annexin V and propidium iodide. (B) SKBR3 cells
with control knockdown (shCtl) or MALT1 knockdown (shMALT1) were mixed with
complete medium containing 1% methylcellulose in the presence or absence of 10ng/ml
heregulin. After 48 hours, apoptotic cells were examined by staining with propidium iodide.
Experiments have been independently repeated 2-3 times.
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Figure 27. The CBM complex is required for anchorage-independent growth of SKBR3
cells in vitro.
(A) SKBR3 cells with control knockdown (shCtl), BCL10 knockdown (shBCL10), or
CARMA3 knockdown by 1 of 2 different shRNAs (shCARMA3-1 and shCARMA3-2) were
subjected to the colony formation assay in the presence or absence of 10 ng/mL heregulin for
2 weeks. Five random fields were photographed; one was presented here. (B) Quantification
of colonies in panel A in the presence or absence of HRG. (C) SKBR3 cells with control
knockdown (shCtl) or MALT1 knockdown (shMALT1) were subjected to the colony
formation assay in the presence of HRG (10 ng/ml). The sizes of the colonies were quantified
and analyzed (right).
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Figure 28. CARMA3 is required for tumor progression on a xenograft mouse model.
SKBR3 cells with control knockdown (shCtl) or CARMA3 knockdown (shCARMA3-2)
were subcutaneously injected on each side of 5 SCID mice to develop xenograft tumors. The
mice were euthanized 6 weeks after injection and size of the tumors was determined.
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3.3.4 The CBM complex contributes to cell migration and invasion
It has been suggested that NF-κB signaling plays a crucial role in cell migration and
invasion (Huber et al. 2004). Therefore, we examined the involvement of the CBM complex
in HRG-induced cell migration and invasion in vitro using the transwell migration assay. We
found that silencing CARMA3 or BCL10 significantly inhibited cell migration (Figure 29A)
and invasion (Figure 29B) in response to either serum or HRG stimulation. Similar results
were also found in SKBR3 cells with silenced MALT1 (Figure 30). These results suggest that
the CBM complex is required for HRG-induced cell migration and invasion in vitro.
To further validate this finding in vivo, we generated a spontaneous lung metastasis
model by injecting CARMA3-silenced and control SKBR3 cells into SCID mice. We found
significantly fewer lung metastatic sites in mice injected with CARMA3-silenced cells than
in mice injected with control cells (Figure 31), suggesting that CARMA3 contributes to
breast cancer metastasis in vivo. Taken together, these results indicate that the CBM complex
contributes to cell migration and invasion in vitro and in vivo.
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Figure 29. CARMA3 and BCL10 are required for serum and HRG induced cell
migration and invasion.
(A) SKBR3 cells with control knockdown (shCtl), BCL10 knockdown (shBCL10), or
CARMA3 knockdown by 1 of 2 different shRNAs (shCARMA3-1 and shCARMA3-2) were
subjected to the transwell migration assay in the presence of either fetal bovine serum or
heregulin (10ng/ml). After 16 hours, cells were fixed, stained, and photographed using
inverted microscope. The number of migrated cells was quantified (right panel). (B) SKBR3
cells with shRNA knockdown as in A were subjected to the invasion assay for 48 hours to
penetrate matrigel. Following incubation, the cells were fixed, stained, and quantified (right
panel).
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Figure 30. MALT1 is required for serum induced cell migration and invasion.
SKBR3 cells with control knockdown (shCtl) or MALT1 knockdown (shMALT1) were
subjected to the transwell migration and invasion assays in the presence of fetal bovine
serum. After 16 hours (for migration) and 24 hours (for invasion), cells were fixed, stained,
and photographed using inverted microscope. The number of migrated cells were quantified.
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Figure 31. CARMA3 is required for lung metastasis in a mouse model.
SKBR3 cells with a control knockdown (shCtl) or CARMA3 knockdown (shCARMA3)
were intravenously injected into 6-week-old female SCID mice. After 6 weeks, mice were
euthanized and lungs were washed, fixed, and stained with Bouin’s solution. The number of
metastatic tumors was quantified and analyzed.
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3.3.5 CARMA3 contributes to migration and invasion through regulating HER2induced MMP1 and MMP13 expression
To further examine the mechanism by which the CBM complex controls cell
migration and invasion, we examined a set of matrix metalloproteinases (MMPs) and found
that the expression levels of MMP1 and MMP13 were significantly upregulated after HRG
stimulation in SKBR3 cells (Figure 32 A-B). In comparison, MMP3 and MMP7 were not
responsive to HRG stimulation whereas MMP14 was downregulated by HRG stimulation
(Figure 32C-E). Furthermore, the induction of MMP1 and MMP13 was significantly blocked
by treatment with an IKK inhibitor (TPCA) or NF-𝜅B translocation inhibitor (NF-𝜅Bi), or
PKC inhibitor (GF109203X), respectively (Figure 33). These data indicate that the induction
of MMP1 and MMP13 depends on PKC- and IKK-mediated canonical NF-B activation in
response to HRG stimulation.
Because the CBM complex is required for NF-𝜅B activation in response to HRG
stimulation, we next determined whether the CBM complex regulates HER2-induced MMP
induction. We found that the induction of MMP1 and MMP13 was significantly blocked in
CARMA3-silenced cells compared with control cells, indicating that CARMA3 is required
for HER2-induced MMP1 and MMP13 expression (Figure 34). Collectively, our results
indicate that the CBM complex-dependent NF-𝜅B pathway regulates MMP1 and MMP13
expression in response to HER2 activation.
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Figure 32. MMP1 and MMP13 are upregulated upon HRG stimulation in SKBR3 cells.
SKBR3 cells were stimulated with (HRG; 50ng/ml) for 6, 12, or 24 hours, respectively. Total
RNA was extracted for quantitative polymerase chain reaction (PCR) analysis. Levels of the
indicated mRNAs were normalized to GAPDH.
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Figure 33. Upregulation of MMP1 and MMP13 depends on PKC-IKK-NF-𝜅B pathway.
SKBR3 cells were stimulated with HRG (50ng/ml) for 24 hours in the presence of the IKK
inhibitor TPCA (IKKi), NF-𝜅B translocation inhibitor SN50 (NF-Bi), or protein kinase C
inhibitor GF109203X (PKCi). Total RNA was extracted for quantitative PCR analysis. Level
of MMP1 and MMP13 were normalized to GAPDH.
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Figure 34. CARMA3 is required for HER2-induced MMP1 and MMP13 upregulation.
SKBR3 cells with control knockdown (shCtl), or CARMA3 knockdown by 1 of 2 different
shRNA (shCARMA3-1 and shCARMA3-2) were stimulated with HRG (50ng/ml) for 24
hours. Total RNA was extracted for quantitative PCR analysis. Levels of MMP1 and MMP13
were normalized to GAPDH.
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3.3.6 MALT1 contributes to breast cancer progression in vivo
To investigate the contribution of the CBM complex contributes to HER2-induced
breast cancer progression, we backcrossed Malt1 knockout mice (Malt1-/-) from a C57BL/6
background to an FVB/N background and then crossed these mice with MMTV-Neu mice to
generate MMTV-Neu; Malt1-/- mice, in which mammary tumors develop in the absence of
Malt1 expression. Both control mice (MMTV-Neu; Malt1+/+ and MMTV-Neu; Malt1+/-) and
Malt1 knockout mice (MMTV-Neu; Malt1-/-) developed mammary tumors owing HER2
overexpression (Figure 35A). However, we found that Malt1 knockout mice (MMTV-Neu;
Malt1-/-) showed longer tumor latency than controls (Figure 35B). In addition, the overall
survival durations in Malt1 knockout mice (MMTV-Neu; Malt1-/-) were significant longer
than in control mice (Figure 35C), indicating that the mammary tumors progressed at a
slower rate in Malt1 knockout mice than in control mice. Together, these data indicates that
MALT1 contributes to HER2-induced mammary tumor progression in vivo.
In summary, this study demonstrated that the CBM complex plays a crucial role in
HER-associated beast tumor by regulating HER-induced NF-𝜅B pathway (Figure 36).
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Figure 35. MALT1 contributes to HER2-induced mammary tumor progression in vivo.
(A) Hematoxylin and eosin staining of mammary tumors developed in MMTV-Neu mice
(upper panel) and immunohistochemistry staining with anti-Neu antibodies of mammary
tumors developed in MMTV-Neu mice (lower panel). (B) Mammary tumor latency was
compared among wild-type mice (Malt1+/+; MMTV-Neu; n=5), Malt1 heterozygous mice
(Malt1+/-; MMTV-Neu; n=16) and Malt1 knockout mice (Malt1-/-; MMTV-Neu; n=9). Logrank test; P=0.0423 (C) The overall survival time of the mice in panel B was calculated and
analyzed. Log-rank test; P=0.0040
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Figure 36. The working model summarizing the findings in this study.
The CARMA3-BCL10-MALT1 complex is required for HER2-mediated NF-𝜅B activation in
breast cancer cells. The HER2-induced NF-𝜅B contributes to many malignant phenotypes of
breast cancers, including proliferation, survival, migration and metastasis. Mechanistically,
NF-𝜅B transcribes MMP1 and MMP13 to facilitate migration and invasion.
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3.4 Discussion
3.4.1 HER2-induced NF-𝜅B is mediated by PKC-CBM-IKK axis instead of AKT
Although NF-𝜅B plays a central role in many aspects of malignancy in HER2positive breast cancer, the molecular mechanism by which HER2 activates NF-𝜅B remains to
be determined. Our previous studies identified the CBM complex as a central mediator of T
cell receptor- and B cell receptor-induced NF-𝜅B activation in lymphoid cells (Wang et al.
2002). In addition, our group and others reported that both GPCR and EGFR utilize the CBM
complex to activate NF-𝜅B in nonhematopoietic cells (Grabiner et al. 2007, Klemm et al.
2007, McAllister-Lucas et al. 2010, Jiang et al. 2011). In the current study, using biochemical
and genetic approaches, we showed that HER2-induced NF-𝜅B activation is mediated by the
CBM complex. In addition, we found that PKC activity is required for the activation of NF𝜅B in response to HRG stimulation. This result is consistent with the idea that PKC is the
upstream activator of CARMA1 or CARMA3 (Blonska and Lin 2011). Thus, we propose that
the PKC-CBM axis is the major pathway that links HER2 to NF-𝜅B activation.
The PKC-CBM axis also mediates EGFR-induced NF-κB activation, as we have
previously shown (Jiang et al. 2011, Pan et al. 2015). Thus, our study reveals a shared
mechanism by which the CBM complex mediates NF-𝜅B activation in response to activation
of the receptors in the EGFR family, and possibly activation of other types of tyrosine kinase
receptors such as fibroblast growth factor receptor, which also activates PKC (Jiang and Lin
2012). Further investigation is needed to determine whether the CBM complex mediates
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NF-𝜅B activation when other types of tyrosine kinase receptors outside of the EGFR family
are activated.

3.4.2 The role of NF-𝜅B in HER2-associated breast tumor progression
A major treatment strategy for HER2-positive breast cancer is to block the HER2
receptor using monoclonal antibodies such as trastuzumab (Mitri et al. 2012). However, the
inevitable obstacle for such therapy is that patients quickly develop drug resistance. Several
preclinical studies showed that a combination of trastuzumab with a PI3K inhibitor
overcomes trastuzumab resistance (Eichhorn et al. 2008, Serra et al. 2008, Junttila et al.
2009), indicating that blocking the major downstream effector pathways is an alternative way
to prevent trastuzumab resistance. Although a previous study suggested that AKT activation
is responsible for NF-𝜅B activity in HER2-overexpressed breast cancer cell lines (Pianetti et
al. 2001), we showed that NF-𝜅B and AKT are indeed 2 independent pathways downstream
of HER2, because the AKT inhibitor did not affect NF-𝜅B activation and the PKC inhibitor
did not affect AKT activation. These findings provide a molecular basis and rationale for
targeting the PKC-CBM complex-NF-𝜅B pathway in HER2-positive breast cancer. It is also
worth examining in the future studies whether combining an NF-𝜅B inhibitor with
trastuzumab and a PI3K inhibitor leads to synergistic effects.
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Using functional assays and mouse models, we also showed that the CBM complex is
required for tumor cell proliferation, survival, and migration. We observed that the CBM
complex is played the most significant role in terms of cell migration and invasion. This
observation is consistent with a previous report that silencing IKK𝛼 abolished NF-𝜅B
activation and decreased the invasiveness of SKBR3 cells (Merkhofer et al. 2010). However,
the mechanism by which NF-𝜅B controls tumor cell migration and invasion remains largely
unknown. In the current study, we sought to determine whether CBM complex-mediated
NF-𝜅B activity affected the expression of MMP family, which is known to play a crucial role
in tumor metastasis. Indeed, we found that MMP1 and MMP13 were highly induced after
HRG stimulation in a PKC-, CARMA3-, IKK complex- and NF-𝜅B-dependent manner,
which strongly suggests that HER2-induced NF-𝜅B is crucial for the induction of these
MMPs. It has been reported that MMP1 and MMP13 are involved in breast cancer
metastasis (Pivetta et al. 2011, Liu et al. 2012)(24, 25). Thus, our data indicate that NF-𝜅B
signaling contributes to cell invasiveness at least in part through MMP1 and MMP13 in
HER2-positive breast cancer cells.
In summary, our data reveal the molecular mechanism by which HER2 activates
NF-𝜅B through PKC and the CBM complex. In addition, our results also highlighted the
contribution of the CBM complex and NF-𝜅B signaling to the characteristics of malignancy
in HER2-positive breast cancer cells and provide a molecular basis for targeting NF-𝜅B
signaling in HER2-positive breast cancer.
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CHAPTER 4. THE ROLE OF CBM COMPLEX IN DNA DAMAGE-INDUCED NF𝜅B ACTIVATION AND RESISTANCE TO CHEMOTHERAPY-INDUCED CELL
DEATH
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4.1 Introduction
4.1.1 General overview DNA repair and DNA damage response
It is estimated that there are about 10,000 of DNA lesions occur within each cells in
our human body each day (Pivetta et al. 2011). As the central hereditary materials in the cell
nuclei, the integrity of DNA is extremely important. If not being repaired properly, DNA
damage can lead to genetic instability and eventually accelerate the onset of cancer. The
causes of DNA damage come from a variety of sources, such as ionizing radiation,
chemotherapeutic drugs, ultraviolet exposure, reactive oxygen species and mechanical stress
on chromosomes. The types of DNA damage includes base modifications, such as
methylation and oxidation, mispairs, which come from mistakes in DNA synthesis, crossliked nucleotides, such as intrastrand and interstrand links, and double-stranded DNA breaks.
Depending on the types of DNA damage, cell utilizes different mechanisms to repair DNA
damage.
Base excision repair (BER) corrects small base DNA lesion most commonly caused
by oxidation, deamination or alkylation. The common steps of BER includes excision,
incision, end processing repair synthesis and ligation (Krokan and Bjoras 2013). Nucleotide
excision repair (NER) is an important mechanism the removes DNA damage induced by
ultraviolet. The NER pathway can be categorized into global genome nucleotide excision
repair (GG-NER) and transcription-coupled nucleotide excision repair (TC-NER) (Marteijn
et al. 2014).

DNA mismatch repair (MMR) is also a highly conserved biological pathway

to maintain genomic stability from E.coli to the mammalian cells. The general role of MMR
is to recognize and correct base substitution mismatches during DNA replication. In E.coli,
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MMR is initiated by MutS, MutL and MutH. MutS is the mismatch recognition protein
which recognizes base-base mismatches or small nucleotide insertion or deletion. After
recognition, MutL, which constantly interacts with MutS, recruits and activates the
endonuclease MutH, which nicks the newly synthesized DNA and corrects the strand. After
nicking, helices II is loaded and generates a single-strand DNA, which binds to SSB (single
stranded DNA-binding protein) and is protected from nuclease attack (Ramilo et al. 2002).
Afterwards, endonuclease such as Exon and RecJ will be recruited to excise the nicked strand
from the nick site and resulting single-stranded gap will be repaired by DNA polymerase III,
SSB and DNA ligase to finish the process. The human MMR pathway is very similar to that
in E.coli, and a defect of MMR pathway is tightly linked to the development of cancer. For
example, it has been shown that germ-line mutations in hMSH2 is associated with hereditary
non-polyposis colorectal cancer (HNPCC) (Fishel et al. 1993, Leach et al. 1993).
In case of double stranded DNA break, cells either utilize homologous recombination
(HR) or non homologous end joining (NHEJ), which are important repair processes to repair
double stranded DNA break. For example, the initial process of NHEJ involves the binding
of the protein complex Ku70/80 heterodimer with both ends of DNA double stranded break.
Subsequently, the Ku70/80 complex will attract DNA-dependent protein kinase catalytic
subunit (DNA-PKCS) to bring the DNA ends together. Meanwhile, nucleases and
polymerases will be recruited to the double stranded break to remove or fill-in single
stranded overhangs. Finally, the ligase/XRCC4 complex will catalyze the ligation process
(Weterings and Chen 2008). The NHEJ plays a particular important role in the V(D)J
recombination, a process in which lymphocytes diversity is generated in the vertebrate
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immune system. The error-prone feature of NHEJ is beneficial and maximize the diversity of
immune receptors (Jung and Alt 2004). By contrast, HR is commonly considered as error
free as it ensure accurate repair by using the other undamaged sister chromatid as a temple.
In addition to DDR, DNA damage can also trigger a variety of cellular processes,
including replisome stability, transcription, cell cycle regulation, metabolic changes and
autophagy, chromatin remodeling, RNA processing and apoptosis. Two key signaling
components in the DDR pathway are protein kinases ATM (Ataxia Telangiectasia Mutated)
and ATR (Ataxia Telangiectasia And Rad3-Related Protein). ATM/ATR phosphorylates a
number of substrates to regulate many cellular processes. For example, upon DNA damage,
ATM/ATR phosphorylate CHK1 (Checkpoint kinase 1) and CHK2 (Checkpoint kinase 2) to
induce cell cycle arrest and apoptosis by inhibition of the activity of cyclin-dependent kinase
(CDK) and stabilization of P53 (Jackson and Bartek 2009).

4.1.2 Molecular mechanism by which DNA damage-induces NF-𝜅B activation
It has been suggested that DNA damage also triggers the activation of NF-𝜅B, which
provides a pro-survival signals to the cell to analogize apoptosis induced by DNA damage
(Janssens and Tschopp 2006). Unlike traditional NF-𝜅B activation induced by extracellular
stimuli, DNA damage-induced NF-𝜅B is activated from a signal from the nuclei. Therefore,
DNA damage-induced NF-𝜅B is also called as “inside out” NF-𝜅B activation (McCool and
Miyamoto 2012). As the central inducer of DDR, ATM is also required for DNA damageinduced NF-𝜅B activation. By using ATM-deficient cells, Piret et al. showed that ATM is
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required for CPT (camptothecin)-induced NF-𝜅B activation (Piret et al. 1999). This study
established a molecular link between ATM and DNA damage-induced NF-𝜅B activation
(Piret et al. 1999). Subsequently, Wu et al. showed that ATM phosphorylates NEMO (IKK𝛾)
at the site (Ser85) to promote its ubiquitin-dependent nuclear export, which also bridges the
nuclear export of ATM (Wu et al. 2006). Since NEMO is an essential component in NF-𝜅B
pathway, this study further established the ATM-NEMO axis in DNA damage-induced NF𝜅B activation (Wu et al. 2006).
Huang et al. showed that the C-terminal zing finger (ZF) of NEMO is required for
ultraviolet- and etoposide-induced NF-𝜅B activation, while ZF domain is largely dispensable
for LPS- and TNF-induced NF-𝜅B activation. This data is one of the earliest mechanistic
insights suggesting DNA damage utilizes key signaling component in the canonical NF-𝜅B
pathway to activate NF-𝜅B. Subsequently, Huang et al. further showed that both sumoylation
and ubiquitination of NEMO by SUMO-1 (Small Ubiquitin-Like Modifier 1) is required for
DNA damage-induced NF-𝜅B activation. Furthermore, the authors showed that ATMindependent SUMO-1-mediated sumoylation of NEMO triggers the nuclear localization of
NEMO. In addition ATM-dependent ubiquitylation of NEMO mediates the activation of the
IKK complex in the cytosol (Huang et al. 2003). Taken together, both studies indicate an
essential role of NEMO in the DNA damage-induced NF-𝜅B pathway.
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Subsequently, a number of studies also indicate the involvement of other signaling
molecules in DNA-damage induced NF-𝜅B pathway. These molecules involve TAK1
(Transforming Growth Factor-Beta-Activated Kinase 1), RIP1 (Receptor-Interacting Protein
1), ELKS (essential regulatory subunit of the IKK complex), PIASy (protein inhibitor of
activated STATy), PIDD (p53-inducible death-domain-containing protein) and TRAF6 (Hinz
et al. 2010, Wu et al. 2010, Yang et al. 2011). However, it still remains unclear that how
NEMO is activated upon DNA damage induction (Figure 37). As a central inducer of
mediating NEMO ubiquitination and activation, here we propose to test a potential role of the
CBM complex in DNA damage-induced NF-𝜅B activation.
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Figure 37. Schematic overview of DNA damage induced NF-𝜅B activation.
DNA damage-induced NF-𝜅B activation requires the activation of ATM, which
phosphorylates NEMO in the nucleus to trigger the nuclear export of NEMO. In addition,
TAK1 and TRAF6 are also believed to mediate the activation of IKK complex. In this model,
the molecular mechanism by which TRAF6 is activated remains unclear.
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4.2 Materials and Methods
4.2.1 Cells
Primary MEFs were generated from E13.5 from Malt1+/- mice. MEFs were grown in
DMEM medium containing 10% fetal bovine serum at 37ºC with 8% CO2.

4.2.2 Doxorubicin-induced apoptosis
To access Doxorubicin-induced cell apoptosis, Annexin V and propidium iodide (PI)
staining was performed. Briefly, doxorubicin (1.5ug/ml) will be introduced into confluent
MEFs in 6-well plate. After 6 hours and 12 hours, respectively, MEFs were digested by
0.05% tripsin and cells will be washed by PBS and suspended in 100𝜇l of 1X binding buffer
provided by Annexin V staining kit (eBioscience, #88-8007). 5𝜇l of Annexin V-FITC will be
added to the cell suspension and will be incubated for 15 minutes at 4 degree. 3𝜇l of PI-APC
will be added to the suspension and will be incubated for 5 minutes at 4 degree. The
suspension will be washed 1 time will 1 X binding buffer and will be suspended in 200𝜇l of
1 X binding buffer. The pro-apoptotic and apoptotic cells will be access by flow cytometry.

4.2.3 Immunoblotting assay
For immunoblotting assay was performed as described (Pan et al. 2015). One million of
cells were lysed in 100𝜇l of lysis buffer (150 mM NaCl, 50 mM HEPES at pH 7.4, 1 mM
EDTA, 1% NP-40, protease inhibitors) for 10 minutes. The cell lysates will be purified by
spinning 13,000 r.p.m. for 10 minutes and resulting supernatants will be saved for western
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blot analysis. 10-12𝜇l of the resulting supernatant were loaded to 10% of SDS-PAGE and
probed with antibodies.

4.2.4 EMSA
EMSA (electrophoretic mobility shift assay) was performed as described (Pan et al.
2015). Two million cells were starved overnight in DMEM containing 0.5% serum and
stimulated with genotoxic reagents, including doxorubicin, VP16, and campththecin. Nuclear
extracts were isolated and were incubated with 1 × 105 c.p.m. of 32P-labeled probes at room
temperature for 15 minutes. The samples were separated on a native Tris-borate-EDTA
polyacrylamide gel and analyzed by autoradiography.

4.2.5 Immunoprecipiation assay
Generally, five million of cells were lysed in 300𝜇l of lysis buffer (150 mM NaCl, 50
mM HEPES at pH 7.4, 1 mM EDTA, 1% NP-40, protease inhibitors) for 10 minutes. The cell
lysates will be purified by spinning 13,000 r.p.m. for 10 minutes and resulting supernatants
will be saved for Immunoprecipiation assay. 30𝜇l of the protein lysis will be saved for
western blot analysis as input. The rest lysis will be incubated together with indicated
antibodies and protein A or protein G agarose beads for overnight at 4 degree. After
incubation, the beads will be washed three times with lysis buffer and will be suspended in
30𝜇l of lysis buffer containing SDS for western blot analysis.
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4.3 Results
4.3.1 MALT1 regulates doxorubicin-induced apoptosis
Since MALT1 contributes to cell survival by regulating growth factor-induced NF-𝜅B
pathway in tumor cells (Pan et al. 2015, Pan et al. 2015), we propose to test whether MALT1
also affects cell death induced by other agents, such as doxorubicin, which is a drug
frequently used in chemotherapy (Lao et al. 2013). To this end, we treated primary Malt1heterozygous MEFs (Malt1+/-) and Malt1-knockout MEFs (Malt1-/-) with 1.5𝜇g/ml of
doxorubicin for 6 hours and 12 hours, respectively. We observed that in MALT1-deficient
MEFs there were more floating cells than controls, indicating that there were more apoptotic
cells in MALT1-deficient MEFs than control cells. We further quantified the dead cells and
apoptotic cells by AnnexinV and PI staining. Before treatment, there was no difference of
combined apoptotic and dead cell population between controls MEFs and MALT1-deficient
MEFs (2.26%+3.18% vs. 2.73%+2.76%) (Figure 38). However, we observed that there were
about 2 fold of combined dead cells and apoptotic cells in MALT1-deficient MEFs compared
with controls for both 6 hours (1.94%+3.33% vs. 4.27%+5.97%) and 8.5 hours (1.68%
+2.95% vs 4.72%+5.07%) after doxorubicin treatment (Figure 38). This data indicates that
MALT1 regulates pro-survival signaling to antagonize doxorubicin-induced apoptosis in
MEFs.
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Figure 38. MALT1 regulates pro-survival signaling to antagonize doxorubicin-induced
apoptosis in MEFs.
Malt1+/- and Malt1-/- MEFs were treated with doxorubicin (1.5𝜇g/ml) for 6 and 8 hours,
respectively. Dead cell and apoptotic cell population were accessed by Annexin V and PI
staining.
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4.3.2 MALT1 is required for DNA damage induced NF-𝜅B activation
Since MALT1 is involved in NF-𝜅B activation in response to many kinds of stimuli,
including antigen receptors, c-type lectin receptors GPCR, EGFR and HER2 (Blonska and
Lin 2011, Pan and Lin 2013), we reasoned that MALT1 may also affects apoptosis by
regulating NF-𝜅B activity in response to DNA damage, as NF-𝜅B provides pro-survival
signals. To this end, we treated control MEFs (Malt1+/-) and MALT-deficient MEFs (Malt1-/-)
with doxorubicin (1.5𝜇g/ml) and examined NF-𝜅B activation by EMSA. We found that
doxorubicin potently induced NF-𝜅B activation in control cells, which is consistent with
previous findings (Janssens and Tschopp 2006). However, doxorubicin-induced NF-𝜅B
activation was completely defective in MALT1-deficient MEFs (Figure 39A), indicating that
MALT1 is required for doxorubicin-induced NF-𝜅B activation.
Doxorubicin is a genotoxic reagent and induces DNA damage by inhibiting the
activity of topoisomerase II, which relaxes the supercoils in DNA for transcription (Pommier
et al. 2010). Therefore, to generalize our finding, we hypothesize that MALT1 is required for
DNA damage induced NF-𝜅B activation. To this end, we treated control MEFs (Malt1+/-) and
MALT-deficient MEFs (Malt1-/-) with two other genotoxic reagent VP16 (etoposide) (10𝜇M)
and CPT (2𝜇M), respectively. Consistent with our hypothesis, both VP16- and CPT-induced
NF-𝜅B activation were defective in MALT1-deficient cells compared with controls (Figure
39B), indicating that MALT1 is required for DNA damage-induced NF-𝜅B activation.
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Figure 39. MALT1 is required for DNA damage-induced NF-𝜅B activation.
(A) MEFs from Malt1+/- and Malt1-/- embryos were isolated. Early-passage (P1) MEFs were
stimulated with doxorubicin (1.5𝜇g/ml) or TNF (10ng/ml) for indicated periods. NF-𝜅B
activation and Oct-1 levels were determined by the gel shift assay. (B) Malt1+/- and Malt1-/MEFs were stimulated with VP16 (10𝜇M), CPT (2𝜇M) or TNF (10ng/ml) for indicated
periods. NF-𝜅B activation and Oct-1 levels were determined by the gel shift assay.
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4.3.3 The CBM complex is required for DNA damage-induced NF-𝜅B activation
MALT1 forms a complex with CARMA3 and BCL10 in non-hematopoietic cells to
activate IKK complex and NF-𝜅B (Blonska and Lin 2009). Therefore, we would like to test
that whether CARMA3 and BCL10 are also involved in DNA damage-induced NF-𝜅B
activation. We isolated CARMA3-deficient (Card10-/-) and BCL10-deficient (Bcl10-/-)
MEFs together with wild-type controls. We treated these cells with doxorubicin and found
that, both CARMA3-deficient and BCL10-deficient cells were completely defective for NF𝜅B activation upon doxorubicin treatment (Figure 40A). This data indicates that CARMA3
and BCL10 are also involved in DNA damage-induced NF-𝜅B activation.
To further test whether the same phenomenon can be observe in other cell types, we
tested Jurkat cells and its derivatives JPM50.6 cells, in which the expression of CARMA1 is
disrupted (Wang et al. 2002). We treated JPM50.6 cells and wild-type Jurkat cells as control
with different types of genotoxic reagents, including doxorubicin (1.5𝜇g/ml), VP16 (10𝜇M),
CPT (2𝜇M), or TNF (10ng/ml) as control. Consistent with the finding in MEFs, we found
that genotoxic reagents-induced NF-𝜅B activation was significantly reduced in JPM50.6 cells
compared with control (Figure 40B), indicating that the CARMA1-BCL10-MALT1 complex
in the hematopoietic cells is also required for DNA damage-induced NF-𝜅B activation. In
addition, all cells showed similar level of P53 stabilization (Figure 40B), indicating the
general DNA damage response is not affected by the CBM complex. Together, these results
indicate that CBM complex specifically mediates DNA damage-induced NF-𝜅B activation.
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Figure 40. The CBM complex is required for DNA damage-induced NF-𝜅B activation.
(A) MEFs from Card10+/+, Card10-/-, Bcl10+/+ and Bcl10-/- embryos were isolated. Earlypassage (P1) MEFs were stimulated with doxorubicin (1.5𝜇g/ml) for indicated periods. NF𝜅B activation and Oct-1 levels were determined by the gel shift assay. (B) Wild-type Jurkat
and 50.6 cells were treated with doxorubicin (1.5𝜇g/ml), VP16 (10𝜇M), CPT (2𝜇M), or TNF
(10ng/ml) for indicated periods. NF-𝜅B activation and Oct-1 levels were determined by the
gel shift assay.
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4.3.4 PKC is not required for DNA damage-induced NF-𝜅B activation
It has been suggested that ATM is required for DNA damage-induced NF-𝜅B
activation (Hinz et al. 2010). In order to verify this finding, we treated primary MEFs with
ATM inhibitor KU55933 (5𝜇M) and examined NF-𝜅B activation upon doxorubicin (1.5𝜇g/
ml) treatment. Consistent with previous findings, inhibition of ATM activity reduced NF-𝜅B
activation induced by genotoxic stress. This result indicates that ATM is required for DNA
damage-indued NF-𝜅B activation.
It has been suggested that CBM complex is activated by PKC, which phosphorylates
CARMA1 at the linker domain upon T-cell activation (Matsumoto et al. 2005). In addition, it
has been reported that doxorubicin can activate PKC delta (PKC𝛿) (Diaz Bessone et al.
2011). Therefore, we hypothesize that the CBM complex is activated by PKC isoform upon
DNA damage induction. To address this hypothesis, we pre-treated primary MEFs with PKC
inhibitor (GF109203X) and induce NF-𝜅B activation by either doxorubicin (1.5𝜇g/ml) or
PMA (100ng/ml). Surprisingly, although PKC inhibitor efficiently blocked PMA-induced
NF-𝜅B activation, it did not affect doxorubicin-induced NF-𝜅B activation (Figure 41). This
data indicates that PKC is not involved in DNA damage-induced NF-𝜅B activation, and
CBM complex is activated through other undefined mechanisms.
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Figure 41. PKC is not required DNA damage-induced NF-𝜅B activation.
(A) Primary MEFs were either left untreated or pretreated with ATM inhibitor KU55933
(5𝜇M), following by treating with doxorubicin (1.5𝜇g/ml). NF-𝜅B activation and Oct-1
levels were determined by the gel shift assay. (B) Primary MEFs were either left untreated or
pretreated with PKC inhibitor GF109203X or caspase inhibitor Z-VAD with indicated doses ,
following by treating with either doxorubicin (1.5𝜇g/ml) or PMA (100ng/ml). NF-𝜅B
activation and Oct-1 levels were determined by the gel shift assay.
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4.3.5 CARMA3 associates with TRAF6 upon DNA damage induction
Our previous study indicates that TRAF6 is inducible associated with MALT1 upon
EGF treatment in A431 cells (Pan et al. 2015). It has also been reported that TRAF6 is
required for DNA damage-induced NF-𝜅B activation (Hinz et al. 2010). However, how
TRAF6 is activated upon DNA damage is not clear. Based on our current data, we
hypothesize that the CBM complex functions upstream of TRAF6 and is required for TRAF6
recruitment. To this end, we generated immortalized MEFs with stable expression of
CARMA3-HA similar at an endogenous level. After treating the CARMA3-HA reconstituted
MEFs with doxorubicin, we immunoprecipitated CARMA3-HA and examined the interacting
protein with CARMA3. Interestingly, we observed inducible association of TRAF6 with
CARMA3 upon doxorubicin treatment (1.5𝜇g/ml) (Figure 42). This data indicate that
CARMA3 recruits TRAF6 upon DNA damage induction. We therefore propose that the CBM
complex functions upstream of TRAF6 to mediate DNA damage-induced NF-𝜅B activation
(Figure 43). The upstream mechanism that activates the CBM complex remains to be
determined in the future.
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Figure 42. CARMA3 inducibly associates with TRAF6 upon doxorubicin treatment.
CARMA3-HA-reconstituted MEFs were treated with doxorubicin (1.5𝜇g/ml) for indicated
time points and CARMA3-HA were immunoprecipitated (IP) with anti-HA antibodies. The
IP samples and lysates were analyzed by immunoblotting using the indicated antibodies.
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Figure 43. Proposed working model of DNA damage-induced NF-𝜅B activation.
DNA damage-induced NF-𝜅B activation requires the activation of ATM, which
phosphorylates NEMO in the nucleus to trigger the nuclear export of NEMO. Upon DNA
damage induction, the CARMA3-BCL10-MALT1 (CBM) complex is activated though a
PKC-independent mechanism. The CBM complex may function to recruit TRAF6 to activate
IKK upon DNA damage induction.
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4.4 Discussion
4.4.1 The CBM complex-mediated NF-𝜅B activation
In this study, we showed that the CBM complex is required for DNA damage-induced
NF-𝜅B activation. This is a particularly interesting finding as the CBM complex is generally
considered only involved in receptors-activated NF-𝜅B, such as antigen receptors (Wang et
al. 2002), c-type lectin receptors (Bertin et al. 2000, Bi et al. 2010, Zhao et al. 2014), GPCR
(Grabiner et al. 2007), EGFR (Jiang et al. 2011, Pan et al. 2015) and HER2 (Pan et al. 2015).
Since the signals come from the nuclei in DNA damage response, our study indicates that the
CBM complex has a broader impact in NF-𝜅B activation in response to stimuli from both
outside and inside the cells.
It has been suggested that TRAF6 is required for DNA damage-induced NF-𝜅B
activation (Hinz et al. 2010). However, the molecular mechanism by which TRAF6-mediates
NF-𝜅B activation upon genotoxic stress induction has not been identified. Generally, TRAF6
functions to activate IKK complex by ubiquitination (Sun et al. 2004), and it is recruited by
an upstream scaffold protein, such as the CBM complex (Sun et al. 2004, Pan et al. 2015).
We have previously shown that MALT1 is required for bridging TRAF6 to IKK complex in
response to EGF stimulation in A431 cells (Pan et al. 2015). Here, we showed that DNA
damage stimulation induced the association between CARMA3 and TRAF6, indicating that
the CBM complex may functions as the upstream component of TRAF6 in response to DNA
damage. Since the CBM complex can induce TRAF6 oligomerization and activation in the T
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cells (Sun et al. 2004), we hypothesize that CBM complex activates TRAF6 upon genotoxic
stress induction.
As the activation of IKK complex requires two parallel signals, including
ubiquitination induced by E3 ligases such as TRAF6 and phosphorylation by kinases such as
TAK1 (Blonska and Lin 2011, Pan and Lin 2013). It has been shown that TAK1 is also
required for DNA damage-induced NF-𝜅B activation, suggesting that TAK1 is likely
responsible for phosphorylation of the IKK complex. It still remains to be determined that
whether the CBM complex is also required for the activation of TAK1. Therefore, future
studies is needed to further characterize the roles of CBM complex in DNA damage
signaling.

4.4.2 The upstream activator of CARMA3
The results of this study revealed a role of CBM complex in DNA damage-induced
NF-𝜅B activation. However, it remains unclear that what is the upstream molecules of the
CBM complex in response to DNA damage. Generally, CARMA1 or CARMA3 is activated
by PKC through phosphorylation in the linker region of CARMA protein. For example, it has
been shown that CARMA1 is activated by PKC𝛽 at the site Ser552 (Matsumoto et al. 2005).
Functionally, phosphorylation of CARMA1 triggers a conformational change and exposes
the CARD domain to recruit BCL10 and MALT1 (Matsumoto et al. 2005, Qiao et al. 2013).
The activated CBM complex forms a oligomerized structure and is able to recruit
downstream molecules such as TRAF6 to activate IKK complex (Qiao et al. 2013).
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However, PKC activity is dispensable for DNA damage-induced NF-𝜅B activation,
indicating either other kinases phosphorylate CARMA3 in response to DNA damage, or
CARMA3 is activated through a different mechanism upon DNA damage. For example,
Moreno-Garcia et al. showed that ubiquitination of CARMA1 regulates NF-𝜅B activation in
lymphocytes (Moreno-Garcia et al. 2010). Therefore, the activation mechanism of
CARMA3 need to be further investigated in the future.

4.4.3 Therapeutic implications
NF-𝜅B provides a pro-survival signal to the cell to antagonize apoptosis signal upon
DNA damage. Therefore, cancer cell may utilize NF-𝜅B signaling as a mechanism to avoid
chemotherapy- and radiotherapy-induced apoptosis. Consistent with this notion, we showed
that doxorubicin-induced cell apoptosis became more efficient in MALT1-deficient cells
compared with control, indicating that NF-𝜅B contributes to the resistance of chemotherapyinduced NF-𝜅B activation. In addition, since NF-𝜅B also plays a role in tumor migration and
invasion (Huber et al. 2004, Pan and Lin 2013, Pan et al. 2015, Pan et al. 2015), DNA
damage response may also potentially promote tumor progression. For instance, Niu et al.
showed that DNA damage induced up-regulation of microRNA-21 to promote cancer cell
migration and invasion in an NF-𝜅B and STAT3 dependent manner (Niu et al. 2012). DNA
damage-induced NF-𝜅B also unregulated the expression of IL-6, which also promote cancer
development by activation of STAT3 signaling (Guo et al. 2012). Therefore, targeting DNA
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damage-induced NF-𝜅B pathway is potentially beneficial when it is combined with
radiotherapy or chemotherapy. The biological outcome of combination with targeting NF-𝜅B
and radiotherapy/chemotherapy need to be tested in the future. Therefore, our study also
provides a molecular basis for targeting the CBM complex to block DNA damage-induced
NF-𝜅B pathway.
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CHAPTER 5. CONCLUSION, DISCUSSION AND FUTURE DIRECTIONS
5.1 Conclusion
The CBM complex is best known for a role in mediating antigen receptor-induced
NF-𝜅B activation in lymphocytes (Blonska and Lin 2011). As NF-𝜅B is absolutely critical for
the activation of lymphocytes, the CBM complex is also crucial for lymphocytes activation.
For the same reason, constitutive activation of CBM complex-mediated NF-𝜅B pathway
leads to lymphoma (Davis et al. 2001). However, the role of CBM complex in solid tumor
has not been explored previously. As increasing numbers of literatures demonstrated a crucial
role of NF-𝜅B signaling in different types of solid tumors, such as lung cancer (Meylan et al.
2009) and breast cancer (Biswas et al. 2004), we propose to investigate a role of the CBM
complex in solid tumor progression.
We found that the CBM complex is required for growth factor-induced NF-𝜅B
activation, including EGFR-induced NF-𝜅B and HER-2-induced NF-𝜅B (Jiang et al. 2011,
Pan et al. 2015, Pan et al. 2015). In the EGFR-induced NF-𝜅B pathway, the CBM complex
functions as a scaffold protein complex to mediate IKK activation by recruiting E3 ligase
TRAF6. In addition, MALT1 is required for many tumor malignant phenotypes in vitro,
including cell proliferation, survival and migration. To further investigate a role of MALT1 in
EGFR-associated malignancy in vivo, we generated a lung cancer mouse model in which
lung adenocarcinoma will be developed in the absence of MALT1. In this model, we further
confirmed that MALT1 is specifically involved in EGFR- but not K-ras-associated lung
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cancer progression. Furthermore, EGFR-MALT-NF-𝜅B signaling axis also contributes to
lung cancer progression in vivo by activating STAT3 pathway though IL-6 expression.
Therefore, our study revealed multi-functional roles of MALT1 in the tumorigenesis and
progression of EGFR-assocaited lung cancer (Pan et al. 2015).
In addition, we also generated a breast cancer mouse model in which HER2associated mammary tumor will be developed in the absence of MALT1 expression.
Consistent with our in vitro finding suggesting a role of MALT1 in HER2-induced NF-𝜅B
activation and HER2-associated malignancy, we found that MALT1 also promotes HER2associated mammary tumor progression in vivo. In addition, MALT1 contributes to HER2associated tumor metastasis by regulating HER2-dependent expression of MMP1 and
MMP13 (Pan et al. 2015). In conclusion, our studies demonstrate the role of CBM complex
and MALT1 in growth-factor-related solid tumor progression, and provide molecular basis of
targeting CBM complex and NF-𝜅B pathway in EGFR- and HER2-associated tumor.
In addition to a role of growth factor receptor-induced NF-𝜅B activation, we also
investigated a role of CBM complex in DNA damage-induced NF-𝜅B activation. DNA
damage-induced NF-𝜅B activation provides a pro-survival signal to the cells to antagonize
cell apoptosis induced by DNA damage response. Therefore, understanding the molecular
mechanism by which DNA damage induces NF-𝜅B activation is particularly important. Here,
we showed that DNA damage-induced NF-𝜅B activation requires the CBM complex. In
addition, CARMA3 is inducibly associated with TRAF6 in response to DNA damage
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induction, suggesting a possible role of CBM complex in recruiting TRAF6 to IKK complex.
However, how CBM complex is activated remains to be investigated. We hypothesize that
either CARMA1/CARMA3 is directly activated by kinases other than PKC, or CARMA1/
CARMA3 is activated by other unknown mechanism, such as ubiquitination. Since DNA
damage-induced NF-𝜅B contributes to DNA damage induced tumor malignancy (Niu et al.
2012), our study provides evidence suggesting CBM complex and NF-𝜅B may serve as
potential therapeutic target in combination with radiotherapy and chemotherapy.

5.2 The protease activity of MALT1
The protease activity is the key to lymphocytes activation. Currently, the substrates of
MALT1 includes A20 (Coornaert et al. 2008), BCL10 (Rebeaud et al. 2008), CYLD (Staal et
al. 2011), RelB (Hailfinger et al. 2011), HOIL-1 (Klein et al. 2015), Regnase-1 (Uehata et al.
2013), Roquin-1 and Roquin-2 (Jeltsch et al. 2014). Most of the substrates are negative
regulators of a variety of cellular activates, including NF-𝜅B activation, JNK activation and
regulation of RNA stability. This notion has been further validated by generation of the
MALT1 protease-deficient mice by three different groups (Gewies et al. 2014, Jaworski et
al. 2014, Bornancin et al. 2015). All of these studies have provided genetic evidence
suggesting a critical role of MALT1 protease activity in lymphocytes activation. However, to
date, the protease activity of MALT1 only functions in the lymphocytes and lymphomas.
In our current study, we determine to analyze a potential role of MALT1 protease
activity in non-hematopoietic cells. However, we found that the protease activity of MALT1
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is completely dispensable for both EGFR-induced NF-𝜅B activation and HER2-induced
NF-𝜅B activation. Our data suggests that the protease activity of MALT1 does not
contributes to growth factor-induced NF-𝜅B activation. Consistent with our biochemical
data, the protease activity of MALT1 is also dispensable for tumor malignant phenotypes in
EGFR-associated tumor cell lines. Therefore, our data suggests that MALT1 plays a
differential role in hematopoietic and non-hematopoietic cells.
The underlying reasons for a differential involvement of MALT1 protease activity
remain to be determined. Here we propose several possibilities. First, as a matter of fact,
many of the substrates of MALT1 are preferentially expressed in T-cells, such as A20 and
RelB. Therefore, the dispensability of MALT1 in growth factor-induced NF-𝜅B activation
may due to a lack of essential substrates in non-hematopoietic cells. Indeed, we are not able
to detect A20 and RelB expression in A431 cells. If this is the case, it also suggest a
differential regulatory mechanism of NF-𝜅B in different cell types. Second, even if substrates
expressed in non-hematopoietic cells, MALT1 may not associate with the substrates upon
EGFR or HER2 activation. For example, it has been reported that MALT1 cleaves CYLD in
lymphocytes upon CD3/CD38 stimulation (Staal et al. 2011). However, we cannot detect the
cleavage of CYLD in A431 cells, suggesting that CYLD may not associate with MALT1
upon EGFR stimulation. Third, although studies suggest that MALT1 becomes activated by
oligomerization upon the formation of CBM complex (Qiao et al. 2013), there is no direct
evidence demonstrating that MALT1 becomes activated upon other types of stimulation, such
as EGFR or HER2 stimulation. It is possible that the activation of MALT1 protease activity
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requires additional signals, which are limited in the hematopoietic cells or even only in the Tcells. For example, Pelzer et al. showed that monoubiquitination of MALT1 is required for
the activation of the protease activity of MALT1 (Pelzer et al. 2013). However, it is unclear
that where is the signal comes from and which E3 ligases are required to induce the
monoubiquitination of MALT1. It also remains unknown that whether monoubiquitination of
MALT1 is specific in T-cells. Therefore, the molecular requirements of activation of the
protease activity of MALT1 remain to be further investigated in both hematopoietic cells and
non-hematopoietic cells.

5.3 Future directions of studies on MALT1
MALT1 has been extensively investigated for 15 years since the discovery of MALT1
as a caspase-like protein in the year of 2000 (Uren et al. 2000). It is now well established
that MALT1 functions as a part the CBM complex and mediates NF-𝜅B activation in
response to TCR or BCR stimulation in the lymphocytes (Ruefli-Brasse et al. 2003). Our
current studies and others have also shown that MALT1 has a similar function in response to
different types of stimuli, such as c-type lectin rector-induced NF-𝜅B activation in myeloid
cells (Bertin et al. 2000, Bi et al. 2010, Zhao et al. 2014), GPCR-induced NF-𝜅B activation
(Grabiner et al. 2007), EGFR-induced NF-𝜅B activation (Jiang et al. 2011, Pan et al. 2015) in
lung cancer cells and HER2-induced NF-𝜅B (Pan et al. 2015) activation in breast cancer
cells. In 2008, a milestone discovery demonstrated that MALT1 does have protease activity
and it is critical to T-cell activation (Coornaert et al. 2008). Subsequently, a number of studies
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also identified many other substrates of MALT1, and they play different roles to either
positively or negatively regulate T-cell activation. Although it is clear that MALT1 and its
protease activity contributes to NF-𝜅B activation and lymphocytes activation, several main
questions regarding to MALT1 need to be addressed in the future.

5.3.1 MALT1 and autoimmune disease
First, three different groups have reported that the protease-deficient MALT1 knockin mice develop spontaneous autoimmune disease (Gewies et al. 2014, Jaworski et al. 2014,
Bornancin et al. 2015). Consistently, we also observed that MALT1-deficient mice developed
autoimmune-like diseases when mice were maintained in FVB/N background (Figure 44). It
has been hypothesized that a deficiency of naive regulatory T-cells (Treg) development in
MALT1 protease-deficient mice contributes the autoimmune disease (Jaworski et al. 2014).
In comparison, Gewies et al. proposed that an excessive IFN𝛾 production causes the
autoimmune disease in MALT1 protease-deficient mice (Gewies et al. 2014). Therefore, the
exact causes for autoimmune diseases in MALT1 and MALT1-protease-deficient mice
remains to be further investigated.

5.3.2 The role of MALT1 in the effector function in Th17 cells
Two groups independently showed that MALT1-deficient mice were resistant to the
induction of experimental autoimmune encephalomyelitis (EAE), an animal model of
multiple sclerosis (Brustle et al. 2012, Mc Guire et al. 2013). This result suggests that
MALT1-deficiency affects the effector functions of inflammatory Th17 cells. Brustle et al.
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further showed that while MALT1 is not required for the differentiation of Th17 cells,
MALT1 is required for the effector function of Th17 cells by affecting IL-17 expression
(Brustle et al. 2012). Since there is only one nonfunctional sequence of putative NF-𝜅B
elements in the mouse Il17a locus (Ruan et al. 2011), it is not likely that MALT1 regulates
IL-17 expression directly through NF-𝜅B. Therefore, the exact mechanism in which MALT1
regulates the effector function of Th17 cells need to be further investigated.
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Figure 44. MALT1 deficient mice develop autoimmune phonotypes.
(A) MALT1 deficient mice develops spontaneous conjunctivitis (left panel). H&E staining
showed a significant neutrophils infiltration at conjunctiva in MALT1 deficient mice
compared with MALT1 heterozygous control (middle panel). Enlarged cervical lymph nodes
in MALT1 deficient mice (right panel). (B) Cytokine level in the serum in MALT1 wild-type
mice (WT) and Malt1-/- (KO) mice, respectively.
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5.3.3 BCL10-independent function of MALT1 in macrophages
Since the activation of MALT1 depends on BCL10 and CARMA1/CARMA3, to date,
all of functions of MALT1 is BCL10-dependent. However, if BCL10 and MALT1 are
functionally overlapping, it raises a general question that why two protein are doing the exact
same function? By using multi-plex cytokines array, we found that MALT1-deficient
macrophages, but not WT or BCL10-deficient macrophages, produced significantly more
CXCL-1 upon LPS stimulation, while the production of other cytokines were not changed or
mildly affected (Figure 45A). We have further confirmed that the expression level of
CXCL-1 is much higher in MALT1-deficient macrophages than WT or BCL10-deficient
macrophages (Figure 45B). These results indicate that MALT1 negatively regulates CXCL-1
production upon macrophage activation, and this function is BCL10-independent.
Importantly, inhibition of MALT1 protease activity produces a similar level of CXCL-1 as
MALT1 -eficient macrophages do (Figure 45C), suggesting MALT1 protease activity is
required to regulate this process. Together, these results indicate that MALT1 and its protease
activity has a novel function in negatively regulating CXCL-1 expression independently of
BCL10 in macrophages. Since the function is BCL10-independent, it also raises an
interesting question: How does protease activity of MALT1 being activated independently of
BCL10? To address this question, we examined the expression level of MALT1 and found
that the expression level MALT1 is significantly induced in macrophages upon LPS and
polyI:C stimulation (Figure 46 A-B). However, MALT1 induction was only found in
macrophages but not in MEFs upon LPS stimulation, suggesting TLR-induced MALT1
expression is a macrophage-specific phenomenon (Figure 46C). This data suggest that
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MALT1 upregulation may serve as an alternative activation mechanism of the protease
activity of MALT1. Efforts have been undertaken by our group to further elucidate a new
exciting role of MALT1 in macrophages and TLR signaling.
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Figure 45. MALT1 and its protease activity negatively regulate CXCL-1 expression in
macrophages.
(A) CXCL-1 level (pg/ml) after LPS or poly I:C stimulation (24hrs) in WT, MALT1 deficient
and BCL10 deficient BMDM, respectively. (B) Relative mRNA level of CXCL-1 upon LPS
stimulation in WT, MALT1 deficient and BCL10 deficient BMDM, respectively. (C) Relative
mRNA level of CXCL-1 upon 6 or 12 hours of LPS stimulation in WT, MALT1 deficient
macrophages and WT macrophages treated with MALT1 inhibitor MI-2 (2𝜇M) (MI-2),
respectively.
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Figure 46. MALT1 is specifically induced in macrophages and functions independently
of BCL10.
(A) The protein level of MALT1 as determined by western blot in BMDM. (B) Relative
mRNA level of MALT1 upon LPS stimulation in BMDM upon 6 hours of LPS and polyI:C
stimulation, respectively. (C) Relative mRNA level of MALT1 6 hours of LPS stimulation in
primary mouse embryonic fibroblast (MEFs).
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